multi-specific antigen-binding molecules having an alternative function to the function of factors v

专利摘要:
  MULTI-SPECIFIC ANTIGEN BINDING MOLECULES HAVING ALTERNATIVE FUNCTION TO THE FUNCTION OF FACTORS VIII, IX EX OF BLOOD COAGULATION, AND BIESPECIFIC ANTIBODY, ITS USES IN THE PREVENTION OR TREATMENT OF HEMORRHAGE, NUTRITION, NUTRITION PHARMACEUTICAL COMPOSITION AND KIT.The present invention relates to several bispecific antibodies that specifically bind to blood coagulation factor IX / blood coagulation factor IX and functionally replace the function of the blood coagulation factor VIII cofactor, that is, the function to promote the activation of the blood clotting factor X by blood clotting factor IX. From these antibodies, multispecific antigen-binding molecules with high activity of functionally substituting blood clotting factor VIII were successfully discovered.
公开号:BR112013012213A2
申请号:R112013012213-7
申请日:2011-11-17
公开日:2020-09-01
发明作者:Tomoyuki Igawa；Tsukasa Suzuki；Zenjiro Sampei；Kazutaka Yoshihashi；Tetsuhiro Soeda；Atsushi Muto；Takehisa Kitazawa；Tetsuo Kojima；Yukiko NISHIDA；Chifumi Imai
申请人:Chugai Seiyaku Kabushiki Kaisha；
IPC主号:

专利说明:

[2] [2] the multispecific antigen-binding molecule of [1], which comprises a first polypeptide comprising a first antigen-binding site that recognizes blood coagulation factor IX and an activated blood coagulation factor IX and a third polypeptide comprising a third peptide binding site that recognizes blood clotting factor IX and / or activated blood clotting factor IX, 5 as well as a second polypeptide comprising a second antigen binding site that recognizes coagulation factor X blood and a fourth polypeptide comprising a fourth antigen binding site that recognizes a blood clotting factor X;
[3] [3] the multispecific antigen-binding molecule of [2], out of 10 that the first and third polypeptides each comprise an antigen-binding site of an H chain or L chain of an antibody against factor IX of blood clotting or activated blood clotting factor IX, respectively; and the second and fourth polypeptides each comprise an H chain or L chain antigen binding site of an antibody against blood clotting factor X, respectively;
[4] [4] the multispecific antigen-binding molecule of [3], wherein the antigen-binding site of the first polypeptide comprises an antigen-binding site comprising CDRs of the H chain that consists of any of the amino acid sequences selected from the following 20 (a1) to (a11), or an antigen-binding site equivalent to these, and the antigen-binding site of the second polypeptide comprises an antigen-binding site comprising H chain CDRs consisting of any one of the selected amino acid sequences from the following (b1) to (b11), or an antigen-binding site functionally equivalent to them: (a1) an antigen-binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 75, 76, and 77 (Q H chain CDRs), respectively; (a2) an antigen binding site comprising a CDR 1, 30 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 78, 79, and 80 (H chain CDRs of Q31), respectively; (a3) an antigen binding site comprising a CDR 1,
[5] [5] the multispecific antigen-binding molecule of [3], wherein the antigen-binding site of the first polypeptide comprises an antigen-binding site, which comprises a variable region of the H chain consisting of any of the sequences amino acids from the following (a1) to (all), or a functionally equivalent antigen-binding site
[6] [6] the multispecific antigen-binding molecule of 13], where the antigen-binding sites included in the third polypeptide and the fourth polypeptide comprise an antigen-binding site that comprises the L chain CDRs that consist of any of the selected amino acid sequences from the following (cl) to (c10), or an antigen binding site functionally equivalent to these: (cl) an antigen binding site comprising a CDR1, 2, and 3 of the chain L of amino acid sequences of SEQ ID NOs: 138, 139, 15 and 140 (L2 L chain CDR), respectively; (c2) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 141, 142, and 143 (LR chain of L45), respectively; (c3) an antigen binding site comprising a CDR1, 20, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 144, 145, and 146 (L chain CDR of L248), respectively; (c4) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 147, 148, and 149 (CDR of the L324 L chain), respectively; 25 (c5) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 150, 151, and 152 (L-chain CDR of L334), respectively; (c6) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 153, 154, 30 and 155 (L377 L chain CDR), respectively; (c7) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 156, 157,
[7] [7] the multispecific antigen-binding molecule of [3], wherein the antigen-binding sites included in the third polypeptide and the fourth polypeptide comprise an antigen-binding site that comprises the variable region of the L chain that consists of in any of the 15 selected amino acid sequences from the following (cl) to (c10), or an antigen binding site functionally equivalent to these: (c1) an antigen binding site comprising an amino acid sequence of the variable chain region L of SEQ ID NO: 56 (variable region of the L2 chain L); (C2) an antigen-binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 57 (L45 variable chain region); (c3) an antigen binding site comprising an amino acid sequence of the L-chain variable region of SEQ ID NO: 58 (L248 L-chain variable region); (c4) an antigen-binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 59 (L324 L chain variable region); (c5) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ 1D NO: 60 (L334 variable chain L region); (c6) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 61 (L377 L chain variable region); (c7) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 62 (L404 L chain variable region 5); (c8) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 63 (L406 variable chain L region); (c9) an antigen binding site comprising 10 amino acid sequence of the L chain variable region of SEQ ID NO: 64 (L chain variable region of L408); and (c10) an antigen-binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 173 (L chain variable region of L180); 15 [8] the multispecific antigen-binding molecule of [3], where the first and second polypeptides further comprise a constant region of the H chain of the antibody, and the third and fourth polypeptides comprise a constant region of the L chain of the antibody;
[9] [9] the multispecific antigen-binding molecule of [3], in 20 that the first and second polypeptides comprise a region constant on the H chain of the antibody, and the third and fourth polypeptides comprise a region constant on the antibody L chain, where the third and fourth polypeptides are a commonly shared L chain;
[10] [10] the multispecific antigen-binding molecule of [8] or 25 [9], wherein the first polypeptide comprises an antibody H chain constant region consisting of any of the amino acid sequences selected from the group consisting of the following (dl) to (d6) or the group consisting of the following (d7) to (d9), and the second polypeptide comprises a constant region of the H chain of the antibody that consists of any of the selected amino acid sequences from a group other than that of the first polypeptide mentioned above: (dl) a H chain constant region of SEQ ID NO: 65 (G4k);
[12] [12] the multispecific antigen-binding molecule of [8] or 20 [9], wherein the first polypeptide comprises any of the antibody H chain selected from the following (a1) to (a14), the second polypeptide comprises any of the antibody H chain selected from the following (b1) to (b12), and the third polypeptide and the fourth polypeptide comprise any of the antibody L chain selected from the following 25 (c1) to (c10): (a1 ) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 1 (Q1-G4k); (a2) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 2 (Q31-z7); 30 (a3) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 3 (Q64-z55); (a4) an antibody H chain consisting of the sequence of a-
[13] [13] the multispecific antigen-binding molecule of [1], wherein the first polypeptide comprises an antigen-binding site that binds to an epitope that overlaps with the epitope that binds to an antibody 5 that consists of the H chain of the antibody of any of (a1) to (a14) and the L chain of the antibody of any of (cl) to (c10) of [12], and the second polypeptide comprises an antigen binding site that binds to an an overlapping epitope that binds to an antibody consisting of the H chain of the antibody from any of (b1) to (b12) and the L chain of the antibody of 10 any of (cl) to (c10) of [12] ;
[14] [14] the multispecific antigen-binding molecule of [8] or
[9] [9], where the first polypeptide comprises any one H chain of the antibody, selected from the following (e1) to (e3), the second polypeptide comprises any one H chain of the antibody selected from the following 15 (f1) to (13), and the third polypeptide and the fourth polypeptide comprise any antibody L chain selected from the group (g 1) to (g4): (e1) an H chain of an antibody that binds to an epitope that overlaps an epitope linked by an antibody consisting of a H-chain of the antibody of any of (a1) to (a14) and an L chain of any of (c1) to (c10) of [12]; (e2) an antibody H chain, in which at least one amino acid residue selected from amino acid residues at positions 34, 35, 49, 61, 62, 96, 98, 100, 100b, and 102 by Kabat numbering in which - 25 or an antibody H chain selected from (e1) is replaced with another amino acid; (e3) an H chain of the antibody, where by the number of Kabat, the amino acid residue at position 34 is isoleucine, the amino acid residue at position 35 is asparagine, glutamine, or serine, the residue of 30 amino acid at position 49 is serine, the amino acid residue at position 61 is arginine, the amino acid residue at position 62 is glutamic acid, the amino acid residue at position 96 is serine or threonine, the amino acid residue in position 98 is lysine or arginine, the amino acid residue at position 100 is phenylalanine or tyrosine, the amino acid residue at position 100b is glycine, or the amino acid residue at position 102 is tyrosine in any H chain of the antibody selected from (e1 ); 5 (f1) an H chain of an antibody that binds to an epitope that overlaps an epitope linked by an antibody that consists of an H chain of the antibody from either (b1) to (b12) of [12 ] and an antibody L chain of any one of (cl) to (c10) of [12]; (f2) an antibody H chain, at least one amino acid residue 10 selected from the amino acid residues at positions 35, 53, 73, 76, 96, 98, 100, and 100a by Kabat numbering on any H chain the antibody of (f1) is replaced with another amino acid; (f3) an H chain of the antibody, in which by the number of Kabat, the amino acid residue at position 35 is aspartic acid, the 15 amino acid residue at position 53 is arginine, the amino acid residue at position 73 is lysine, the amino acid residue at position 76 is glycine, the amino acid residue at position 96 is lysine or arginine, the amino acid residue at position 76 is tyrosine, the amino acid residue at position 100 is tyrosine, or the amino acid residue at position 100a is histidine in any antibody H 20 chain selected from (f1); (g1) an L chain of an antibody that binds to an epitope that overlaps with an epitope linked by an antibody consisting of an H chain of the antibody from either (a1) to (a14) and an L chain the antibody of any of (c1) to (c10), of [12]; 25 (g2) an L chain of an antibody that binds to an epitope that overlaps with an epitope attached by an antibody that consists of an H chain of the antibody from either (b1) to (b12) and a chain L of the antibody of any of (cl) to (c10), of [12]; (g3) an antibody L chain, where at least one amino acid residue 30 is selected from amino acid residues at positions 27, 30, 31, 32, 50, 52, 53, 54, 55, 92, 93, 94, and 95 by the numbering of Kabat in the L chain of the antibody or (g1) or (g2) is replaced with another amino
[15] [15] the multispecific antigen-binding molecule from [1] to 15 [14], where the multispecific antigen-binding molecule is a multispecific antibody;
[16] [16] a bispecific antibody from any one of (a) to (u): (a) a bispecific antibody (Q1-G4k / J268-G4h / L45-k), where the first polypeptide is an H chain consisting of amino acid sequence of SEQ ID NO: 1, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 4, and the third polypeptide and fourth polypeptide are a commonly shared L chain. that of SEQ ID NO: 9; (b) a bispecific antibody (Q1-G4k / J268-G4h / L45-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 1, the second polypeptide is a H chain consisting of the amino acid sequence of SEQ ID NO: 5, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 9; (C) a bispecific antibody (Q31-z71J326-z1071L2-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 2, the second polypeptide is an H chain that consists of -
[17] [17] a nucleic acid encoding the multispecific antigen-binding molecule of any one of [1] to [15] or the bispecific antibody of [161;
[18] [18] a vector inserted with the nucleic acid of [17]; 20 [19] a cell comprising the nucleic acid of [17] or the vector of [18];
[20] [20] a method for producing the multispecific antigen-binding molecule of any one of [1] to [15] or the bispecific antibody of
[16] [16] for cultivating the [19] cell; [21] a pharmaceutical composition comprising the multispecific antigen-binding molecule of any one of [1] to [15] or the specific antibody of [16], and a pharmaceutically acceptable carrier;
[22] [22] the composition of [21], which is a pharmaceutical composition used in the prevention and / or treatment of bleeding, a hemorrhage that accompanies a disease, or a disease caused by bleeding;
[23] [23] the composition of [22], in which the bleeding, the bleeding that accompanies a disease, or the disease caused by bleeding is a disease that develops or progresses due to a decrease or deficiency in the activity of coagulation factor VIII blood and blood clotting factor VIII, activated;
[24] [24] the composition of [23], in which the disease that develops 5 and progresses due to a decrease or deficiency in the activity of blood clotting factor VIII and / or activated blood clotting factor VIII is hemophilia A;
[25] [25] the composition of [23], in which the disease that develops and / or progresses due to a decrease or deficiency in the activity of blood clotting factor 10 VIII and an activated blood clotting factor VIII is a disease which shows the emergence of an inhibitor against blood clotting factor VIII and an activated blood clotting factor VIII;
[26] [26] the composition of [23], in which the disease that develops 15 and progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or activated blood coagulation factor VIII, is acquired hemophilia;
[27] [27] the composition of [23], in which the disease that develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor 20 VIII and an activated blood coagulation factor VIII is von Willebrand;
[28] [28] a method to prevent or treat hemorrhage, a hemorrhage that accompanies a disease, or disease caused by hemorrhage, which comprises the step of administering the specific multi-antigen-binding molecule to anyone from [1] to [ 15] or the specific antibody of [16], or the composition of any of [21] to [27]; and
[29] [29] a kit for use in prevention and in the treatment method of [28], which comprises at least the multi-specific antigen-binding molecule of any one of [1] to [15] or the specific antibody of [16] ], or 30 the composition of any of [21] to [27]. In addition, the present invention relates to:
[30] [30] use of the multispecific antigen-binding molecule of any one of [1] to [15], the bispecific antibody of [16], or the composition of any one of [21] to [27] in the manufacture of an agent to prevent or treat bleeding, bleeding that accompanies a disease, or disease caused by bleeding, and 5 [31] the multispecific antigen-binding molecule of any one of [1] to [15], the specific antibody of [16], or the composition of anyone from [21] to [27] to prevent and treat hemorrhage, a hemorrhage that accompanies a disease, or a disease caused by hemorrhage; The present invention also relates to bispecific antibodies that functionally replace F.VIII, a cofactor that enhances enzymatic reactions, and pharmaceutical compositions that comprise the antibody as an active ingredient, and, more specifically, refer to:
[32] [32] a specific antibody that functionally substitutes blood coagulation factor 15 VIII, which comprises a first antigen binding site that recognizes blood coagulation factor IX and a blood coagulation factor IX and an antigen binding site that recognizes blood clotting factor X, where the bispecific antibody is any of the following (a) to (u): 20 (a) a bispecific antibody (Q1-G4k / J268-G4h / L45-k), where the first polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 1, the second polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 4, and the third polypeptide and the fourth polypeptide is an L chain commonly shared with SEQ ID NO: 9; (b) a bispecific antibody (Q1-G4k / J268-G4h / L45-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 1, the second polypeptide is a chain H consisting of the amino acid sequence of SEQ ID NO: 5, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 9; (c) a bispecific antibody (Q31-z71J326-z1071L2-k), where the first polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 2, the second polypeptide is an H chain that consists of te in the amino acid sequence of SEQ ID NO: 6, and the third polypeptide and the fourth polypeptide are an L chain are commonly shared from 5 SEQ ID NO: 8; (d) a bispecific antibody (Q64-z551J344-z1071L45-k), wherein the first polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 3, the second peptide is an H chain that consists of the sequence of amino acids of SEQ ID NO: 7, and the third polypeptide and the fourth polypeptide are an L chain of SEQ ID NO: 9; (e) a bispecific antibody (Q64-z7 / J326-z1071L334-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide is an H chain consisting of second amino acid sequence of SEQ ID NO; 6, and 15 the third polypeptide and the fourth polypeptide are a shared L chain of SEQ ID NO: 30; (f) a bispecific antibody (Q64-z7IJ344-zí07 / L406-k), where the first polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 10, the second polypeptide is an H chain that consists of amino acid sequence of SEQ ID NO: 6, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (g) a bispecific antibody (Q85-G4k / J268-G4h / L406-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 11, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 4, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (h) a bispecific antibody (Q85-G4k / J321-G4h / L334-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 11, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 5, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; (i) a bispecific antibody (Q153-G4k / J232-G4h / L406-k), where the first polypeptide is an H chain consisting of the 5 amino acid sequence of SEQ ID NO: 12, the second polypeptide is an H chain which consists of the amino acid sequence of SEQ ID NO: 21, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (j) a bispecific antibody (Q354-z1061J259-z1071L324-k), out of 10 that the first polypeptide is an H chain that consists of the r amino acid sequence of SEQ ID NO: 13, the second polypeptide is an H chain that consists of amino acid sequence of SEQ ID NO: 22, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 29; 15 (k) a bispecific antibody (Q360-G4kIJ232-G4h / L406-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 14, the second polypeptide is an H chain consisting of in the amino acid sequence of SEQ 1D NO: 21, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (I) a bispecific antibody (Q360-zl 1 8 / J300-zl 07 / L334-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 15, the second polypeptide is a H chain consisting of the amino acid sequence of SEQ ID NO: 23, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; (m) a bispecific antibody (Q405-G4kIJ232-G4h / L248-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 16, the second polypeptide is an H 30 chain consisting of in the amino acid sequence of SEQ ID NO: 21, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 28;
[33] [33] a nucleic acid encoding the bispecific antibody of
[32] [32]; 20 [34] a vector inserted with the nucleic acid of [33];
[35] [35] a cell comprising the nucleic acid of [33] or the vector of [34];
[36] [36] a method for producing the bispecific antibody of [32] by culturing the [35] cell; [37] a pharmaceutical composition comprising the bispecific antibody of [32], and a pharmaceutically acceptable carrier;
[38] [38] the composition of [37], which is a pharmaceutical composition used in preventing and treating hemorrhage, a hemorrhage accompanying a disease, or a disease caused by hemorrhage; 30 [39] the composition of [381, in which hemorrhage, the disease accompanying the bleeding, or the disease caused by hemorrhage is a disease that develops or progresses due to a decrease or impairment.
[40] [40] the composition of [39], in which the disease that develops and progresses due to a decrease or deficiency in the activity of factor 5 VII] blood clotting and factor VIII, activated, is hemophilia;
[41] [41] the composition of [39], in which the disease that develops and progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and a blood coagulation factor VIII, activated, is a disease that shows emergence of an inhibitor against blood clotting factor VIII and / or activated blood clotting factor VIII;
[42] [42] the composition of [39], in which the disease that develops or progresses due to a decrease or deficiency in the activity of blood coagulation factor 15 VIII and a blood coagulation factor VIII, activated, is acquired hemophilia;
[43] [43] the composition of [39], in which the disease that develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and a blood coagulation factor VIII, activated, is the disease von Willebrand;
[44] [44] a method to prevent and / or treat hemorrhage, a hemorrhage accompanying a disease, or a disease caused by hemorrhage, or a disease caused by hemorrhage, which comprises the step of administering the bispecific antibody of [32 ] or the composition of [37] to [43]; 25 [45] a kit for use in prevention and a method of treating
[44] [44], which comprises the bispecific antibody of [32], or the composition of any of [37] to [43];
[46] [46] use of the bispecific antibody of [32] or the composition of any of [37] to [43] in the manufacture of an agent to prevent and / or treat hemorrhage, a disease accompanying a hemorrhage, or a disease caused by bleeding, and
[47] [47] the bispecific antibody of [32] or the composition of any
either one of [37] to [43] to prevent and treat hemorrhage, a disease that accompanies a hemorrhage, or a disease caused by hemorrhage.
Effects of the Invention The present invention provides antibodies that recognize both an enzyme and its substrate, which are multispecific antigen-binding molecules, have a high activity of functionally replacing F.VIII.
In addition, the present invention provides antibodies that recognize both an enzyme and its substrate, which are multispecific antigen-binding molecules with a high activity of functionally replacing F.Vlll and a low inhibitory action of F.Xase.
Since humanized antibodies are believed to have high blood stability and immunogenicity, the multispecific antibodies of the present invention can be quite promising as pharmaceutical products.
Brief Description of the Drawings 15 Figure 1 describes the inhibitory action of F.Xase. (a) F.Vllla forms a complex with F.IXa (F.Xase) and activates F.X. (b) A bispecific antibody that binds to F.IXa and F.X and activates F.X. (c) Both F.Vllla and the bispecific antibody activate F.X without competition; (d) The binding of the bispecific antibody to F.lXa and / or F.X inhibits the formation of the complex formed between F.Xase and F.X. (e) Binding of the bispecific antibody to F. [Xa and / or F.X inhibits F.Xase activity. 25 Figure 2 describes the selection.
Approximately 200 types of each of the genes for antibodies to human F.IXa and human FX were produced, and they were incorporated into animal cell expression vectors, 40,000 or more bispecific antibodies as a combination of an anti-F antibody. .IXa and an anti-FX antibody were transiently expressed.
The activity promoting F.Xa generation and the inhibitory action of F.Xase were evaluated for selection for specific antibodies with a high activity promoting F.Xa generation and low inhibitory action of
I: i F.Xase. In addition, replacing amino acids when necessary led to the production of prototype antibodies. Figure 3 shows the F.Xa promoting activities of hA69- KQIhB26-PFIhAL-AQ, Q 1 -G4k / J268-G4h / L45-k, Q1-G4kJJ321-G4h / L45-k, 5 Q31-z71J326-zl071L2- k, and Q64-z551J344-zl071L45-k. The concentrations of the antibody solutions were 300, 30, and 3 pglmL (the concentrations after mixing Human Factor IXa, Novact (trademark) M, human Factor X, and the antibody solution was 100, 10, and 1 pg / mL), the enzymatic reaction and color development were carried out for ten minutes and 50 minutes, respectively. As a result, these antibodies showed a greater F.Xa generation-promoting activity compared to hA69-KQIhB26-PF / Hal-AQ described in WO 20061109592.
1 Figure 4 shows the F.Xa generation activity of hA69-KQ / hB26-PFIHal-AQ, prototype antibodies, and modified antibodies with amino acid substitutions. The concentrations of the antibody solutions were 300, 30, and 3 pglmL (the concentrations after mixing Human Factor IXa, Novact (trademark) M, human Factor X, and the antibody solution was 100, 10 and 1. g / mL, the enzymatic reaction and the color revision were carried out for two minutes and 20 minutes, respectively. As a result, these modified antibodies showed a greater activity of F.Xa generation in comparison with prototype antibodies Figure 5 shows the F.Xase inhibitory action of hA69-KQIhB26-PFIHal-Aq, prototype antibodies, and modified antibodies with 25 amino acid substitutions. The figure shows the effects of hA69- KQIhB26-PF / hAL- AQ, Q1-G4kIJ268-G4hIL45-k, Q31-z71J326-z107 / L2-k, QI-G4kIJ321- G4hIL45-k, Q64-z551J344-z107 / L45-k, Q85-G4k / J85-G4k / J26 G4h / L406-k, Q85- G4kIJ321-G4h / L334-k, Q64-z71J344-z107 / L406-k, Q64-z7IJ326-z1071L334- k, Q153-G4kIJ142-G4h / L180-k, J405-G4-G4 G4h / L248-k, Q360-30 G4k / J232-G4h / L406-k, Q153-G4kIJ2 32-G4h / L406-k, Q458-zl061J346-zl 07 / L408-k, Q360-z118 / J300-z107 / L334-k, Q499-z1181J327-z107 / L377-k, Q499-z 121 / J 327-zl I 9 / L404-k, Q499-zl 21 / J 339-z 119 / L377-k, Q499-
z1181J346-zl 071L248-k, Q354-zl 061J259-z1 071L324-k, Q460-zl 211J327- z1191L334-k, and Q499-z1181J327-z1071L334-k in the activation of F.X by F.IXa in the presence of F.Vllla.
The inhibitory actions of F.Xase of the antibodies are indicated as the value obtained by subtracting the absorbances of the antibody-free reaction solution from the absorbances of the reaction solution supplemented with antibodies.
The concentrations of the antibody solutions were 300 and 30 pglmL (the concentrations after mixing Human Factor IXa, F.Vllla, human Factor X and the antibody solution were 100 and 10 pglmL), the enzymatic reaction and the development of color were performed for six minutes 10 and 4 minutes, respectively.
The more positive the value of the inhibitory action of F.Xase shown on the horizontal axis, the weaker the inhibitory action of F.Xase.
As a result, hA69-KQIhB26-PF / Hal-AQ described in WO 20061109592 showed strong inhibitory action of F.Xase.
All of the antibodies of the present invention showed inhibitory action of F.Xase inhibitory in comparison with hA69-KQIhB26-PF / Hal-AQ, or showed no inhibitory action.
Figure 6A shows the amino acid sequences of the prototype antibodies and the modified antibodies with amino acid substitutions.
When the sequence name is not indicated in the Ref column, the sequence of the variable region in the Name column is mentioned.
A "- (hyphen)" 20 is shown where an amino acid is missing from the number by Kabat numbering.
A ". (Dot)" is shown where the amino acid is the same when compared to the variable region of the Name column and the Ref column.
And the amino acid from the variable region of the Nome column is shown where the amino acids are different.
Amino acids are considered important 25 for the improvement of the promoting activity of generation F.Xa, they were indicated when they were stricted.
Figure 6B is a continuation of Figure 6A.
Figure 6C is a continuation of Figure 6B.
Figure 6D is a continuation of Figure 6C. 30 Mode for Carrying Out the Invention The multispecific antigen binding molecules described here comprise a first antigen binding site and a second i site:
antigen-binding agents that can specifically bind to at least two different types of antigens.
Although the first antigen binding site and the second antigen binding site are not particularly limited as long as they have activity to bind to F.XI and F.1Xa, and FX, 5 respectively, the examples include sites necessary for binding with antigens, such as antibodies, framework antibodies (antibody-like molecules) or peptides, or fragments containing such sites.
Framework molecules are molecules that exhibit function by binding to target molecules, and any peptide can be used as long as they are stable conformation polypeptides that can bind to at least one target antigen.
Examples of such polypeptides include variable regions of antibodies, fibronectin (WO 20021032925), protein A domain (WO 19951001937), LDL receptor A domain (WO 20041044011, WO 2005/040229), ankine (WO 2002 / 020565), and others, and also molecules described in the documents by Nygren et al. (Current in Structural Biology, 7: 463-469 (1997); and Journal of Immunol Methods, 290: 3-28 (2004)), Binz et a1. (Nature Biotech 23: 1257-1266 (2005)), and Hosse et al. (Protein Science 15: 14-27 (2006)). In addition, as mentioned in Curr Opin Moi Ther. 2010 Aug; 12 (4): 487-95 and Drugs. 2008; 68 (7): 901-12, peptide molecules that can bind target antigens can be used.
Here, multispecific antigen binding molecules are not particularly limited as long as they are molecules that can bind to at least two different types of antigens, but examples include polypeptides containing the above mentioned antigen binding sites, 25 such as antibodies and framework molecules as well as fragments thereof, and aptamers that comprise nucleic acid molecules and peptides, and can be simple molecules or multimers thereof.
Preferred multispecific antigen-binding molecules include multispecific antibodies that can specifically bind to at least two different antigens.
Particularly preferred examples of antibodies that have the function of functionally substituting F.VIII of the present invention include bispecific antibodies (BsAb) that can specifically bind to two different antigens (they can be called dual specific antibodies). In the present invention, the term "commonly shared L chain" refers to an L chain that can bind to two or more different H chains, and show binding capacity to each antigen.
Here, the term "different H chain (s)" preferably refers to, but not limited to, H chains of antibodies against different antigens, and also refers to H chains whose amino acid sequences are different one of others.
The shared L chain can be obtained, for example, according to the method described in WO 20061109592. 10 The multispecific antigen-binding molecules of the present invention (preferably, bispecific antibodies) are antibodies having specificity for two or more different antigens, or molecules comprising such antibodies.
Monoclonal antibodies used in the present invention in the present invention include not only antibodies derived from antibodies such as humans, mice, rats, hamsters, rabbits, sheep, camels, and mace, but also include recombinant antibodies of artificially modified gene such as chi antibodies. - humans, humanized antibodies, and bispecific antibodies.
In addition, the L chains of an antibody that will become a multispecific antigen binding molecule of the present invention may be different, but preferably have L chains commonly shared.
The multispecific antigen-binding molecules of the present invention are preferably recombinant antibodies produced using the genetic recombination technique (see, for example, Borrebaeck CAK and Larrick JW, THERAPEUTIC MONOCLONAL ANTIBODIES, Published in England by MACMILLAN PUBLISHERS LTD, 1990). The recombinant antibodies can be obtained by cloning DNAs that encode antibodies from hybridomas or antibody-producing cells, such as sensitized lymphocytes, that produce antibodies, inserting them into the appropriate vectors, and then introducing them into the hosts (host cells) to produce antibodies.
In addition, the antibodies of the present invention can include not only whole antibodies, but also antibody fragments and low molecular weight antibodies (minibodies), and modified antibodies.
For example, antibody fragments and minibodies include 5 diabody (Dbs), linear antibodies, and single chain antibody molecules (hereinafter called scFvs). Here, an "Fv" fragment is defined as the minor antibody fragment that comprises a complete antigen recognition site and a binding site.
An "Fv" fragment is a dimer (VH-VL dimer) in which an H chain variable region (VH) and an L chain variable region (VL) are strongly linked by a non-covalent bond.
The three complementarity determining regions (CDRs) of each of the variable regions interact with one another to form an antigen binding site on the surface of the VH-VL dimer.
Six CDRs confer the antigen binding site to an antibody.
However, a variable region alone (or half of the Fv that comprises only three CDRs specific for an antigen) can recognize and bind to an antigen, although its affinity is less than that of the entire binding site.
A Fab fragment (also called F (ab)) still comprises an L chain constant region and an H chain constant region (CH1). A Fab 'fragment differs from a Fab fragment in that it additionally comprises several residues derived from the carboxyl terminus of the CH1 region of the H chain, which comprises one or more cisterns of the antibody hinge region.
Fab'-SH refers to a Fab ', in which one or more 25 cysteine residues from its constant region comprise a free thiol group.
An F (ab ') fragment is produced by cleaving disulfide bridges between cistern residues in the hinge region of the F (ab') 2 digested digester. Other fragments of chemically linked antibodies are also known to those skilled in the art. 30 Diabodies are bivalent antibodies constructed by gene fusion (Holliger, P. et al., Proc.
Natl.
Acad.
Sci.
USA 90: 6444-6448 (1993); EP 404,097; WO 93111161). Diabodies are dimers that consist of two chambers
polypeptide chains, in which each polypeptide chain comprises a variable region of the L chain (VL) and a variable region of the H chain (VH) linked with a linker short enough to prevent the association of these two domains within the same chain, for example For example, a linker preferably from 2 to 12 amino acids, more preferably from 3 to 10 amino acids, particularly from 3 to 10 amino acids, particularly from about 5 amino acids.
The polypeptide chain forms a dimer since the linker between VL and VH encoded in the same polypeptide is too short to form a single chain variable region fragment.
Therefore, diabodies comprise two antigen binding sites.
A single chain antibody or a scFv antibody fragment comprises the VH and VL regions of an antibody, and these regions exist on a single polypeptide chain.
In general, an Fv polypeptide further comprises a polypeptide linker between the VH and 15 VL regions, and this allows an scFV to form a necessary structure for antigen binding (for review on scFvs, see Pluckthun "The Pharmaco- logy of Monoclonal Antibodies "Vol. 113 (Rosenburg and Moore ed. (Springer Verlag, New York) pp.269-315, 1994). In the context of the present invention, ligands are not particularly limited as long as they do not inhibit ex 20 pressure of the variable regions of the antibody linked at its ends.
Specific IgG-like antibodies can be secreted from hybrid hybridomas (quadromas) produced by fusion of hybridomas that produce IgG antibodies (Milstein C et al.
Nature 1983, 305: 537-540). They can also be secreted by taking the L chain and H chain genes constituting the two types of IgGs of interest, a total of four types of genes, and introducing these into cells that coexpress the genes.
In this case, when introducing amino acid substitutions in the CH3 regions of the H chains, IgGs having a heterogeneous combination of the H chains can be preferentially secreted (Ridgway JB et al.
Protein 30 Engineering 1996, 9: 617-621; Merchant AM et at.
Nature Biotechnology 1998, 16: 677-681; WO 2006/106905; Davis JH etal.
Protein Eng Des Sel. 2010.4: 195-202).
Referring to L chains, since the diversity of the variable regions of the L chain is less than that of the variable regions of the H chain, the commonly shared L chains that can confer the ability to link to both H chains can be obtained .
The antibodies of this invention comprise commonly shared L chains.
Bispecific IgGs can be effectively expressed by introducing the genes of the commonly shared L chain and both H chains into cells.
Bispecific antibodies can be produced by chemical cross-linking of the Fabs.
Bispecific F (ab ') 2 can be produced, for example, by preparing Fab's of an antibody, using it to produce a Fab' maleimidized with ortho-phenylenedimleimide (o-PDM), and then this region with Fab 'prepared at from another antibody to cross-link Fab's derived from different antibodies (Keler T et al.
Cancer Research 1997, 57: 4008-4014). The method of chemically attaching a Fab'-15 trionitrobenzoic (TNB) derivative and an antibody fragment such as Fab'-thiol (SH) is also known (Brennan M et al.
Science 1985, 229: 81-83). Instead of chemical cross-linking, a leucine zipper derived from Fos and Jun can be used as well.
Preferential formation of heterodimers by Fos and Jin is used, although they can also form homo- 20 dimers.
Fab 'to which the Fos leucine zipper is added, and another Fab' to which another Jun leucine zipper is added are expressed and prepared.
Monomeric Fab'-Fos and Fab'-Jun reduced under mild conditions are mixed and reacted to form F (ab ') 2 (Kostelny SA et al.
J. of Immunology, 1992, 148: 1547-53). (Kostelny SA et al.
J. of Immunology, 25 1992, 148: 1547-53). This method can be applied not only to Fab's, but also to scFvs, Fvs, and others.
In addition, bispecific antibodies including SC (Fv) 2 such as IgG-scFv (Protein Eng Des Sel. 2010 Apr; 23 (4): 221-8) and BiTE (Drug Disc Today. 2005 Sep 15; 10 (18 ): 1237-44.), DVD-lg (Nat Biotechnol. 2007 30 Nov; 25 (11): 1290-7. Epub 2007 Oct 14 .; and MAbs. 2009 Jul; 1 (4): 339-47. Epub 2009 Jul 10.), and others as well (IDrugs 2010, 13: 698-700) including two-in-one antibodies (Science. 2009 Mar 20; 323 (5921): 1610-4; and Immu-
notherapy. 2009 Sep; 1 (5): 749-51.), Tri-Fab, scFv tandem, and diabodies are known (MAbs. 2009 November; 1 (6): 539-547). In addition, even when molecular forms are used, such as scFv-Fc and scaffold-Fc, bispecific antibodies can be produced effectively by preferential secretion of a heterologous combination of Fcs (Ridgway JB et al., Protein Engineering 1996 , 9: 617-621; Merchant AM et al.
Nature Biotechnology 1998, 16: 677-681; WO 20061106905; and Davis JH et al., Protein Eng Des Sei. 2010, 4: 195-202.). A bispecific antibody can also be produced using a diabody.
A bispecific diabody is a heterodimer of two scFV crossover fragments.
More specifically, it is produced by forming a heterodimer using VH (A) -VL (B) and VH (B) -VL (A) prepared by binding VHs and VLs derived from two types of antibodies , A and B, using a relatively short binder of about 5 residues (Holliger P 15 etal.
Proc Nati.
Acad.
Sci.
USA 1993, 90: 6444-6448). The desired structure can be obtained by linking two scFvs with a flexible and relatively long linker comprising about 15 residues (single-stranded body: Kipriyanov SM et al.
J. of Molecular Biology. 1999, 293: 41-56), and making appropriate a-20 minoacid substitutions (button-in-holes: Zhu Z et al.
Protein Science. 1997, 6: 781- 788; VHNL interface engineering: Igawa T et al.
Protein Eng Des Sel. 2010, 8: 667-77). An SC (Fv) 2 that can be produced by linking two types of scFvs with a flexible and relatively long linker, comprising about 25 of 15 residues, can also be a bispecific antibody (Mallender WD etal.
J. of Biological Chemistry, 1994, 269: 199-206). Examples of modified antibodies include antibodies bound to various molecules, such as polyethylene glycol (PEG). The antibodies of the present invention include such modified antibodies.
In the context of the present invention, the substance to which the modified antibodies are attached is not limited.
Such modified antibodies can be obtained by chemically modifying the obtained antibodies.
Such methods are well established in the art.
The antibodies of the present invention include human antibodies, mouse antibodies, rat antibodies, and the like, and their origins are not limited.
They can also be genetically modified, such as chimeric or humanized antibodies.
Methods for obtaining human antibodies are well known in the art.
For example, transgenic animals that contain the entire repertoire of human antibody genes can be immunized with desired antigens to obtain human antibodies (see International Patent Applications WO 93/12227, WO 92103918, WO 94102602, WO - 94 / 25585, WO 96/34096, and WO 96/33735). Genetically modified antibodies can also be produced using known methods.
Specifically, for example, chimeric antibodies can comprise variable regions of the H chain and the L chain of an immunized animal antibody, and constant regions of the H chain and L chain of a human antibody.
Chimeric antibodies can be obtained by binding DNAs that encode the variable regions of the antibody derived from the immunized animal, with the DNAs encoding the constant regions of a human antibody, inserting it into a vector of expies, and then introducing it into the host cells to produce antibodies.
Humanized antibodies are modified antibodies often referred to as "remodeled" human antibodies. A humanized antibody is constructed by transferring the CDRs of an antibody derived from an immunized animal to the complementary determining regions of a human antibody.
Conventional genetic recombination techniques for such purposes are known (see Patent Application Publication EP 239400; International Publication WO 96102576; Sato K et al., Cancer Research 1993, 53: 851-856; International Publication WO 99151743 ). The multispecific antigen-binding molecules of the present invention are those that recognize FIX and / or F.IXa, and FX, and functionally replace the F.VIII cofactor function, and are characterized by the fact that the molecules have generation-promoting activity higher F.Xa compared to hA69-KQIhB26-PFlhAL-AQ (described in WO 20061109592), which is known as a bispecific antibody that functionally replaces F.VIII.
In addition, the antibodies of the present invention 5 usually have a structure comprising an anti-F.Xa antibody variable region and an anti-F.X antibody variable region.
More specifically, the present invention provides a multispecific antigen-binding molecule that functionally replaces F.VIII, which comprises a first antigen-binding site that recognizes FIX and FIXa, and a second antigen-binding site which recognizes FX, in which the function that replaces the F.VIII function is caused by activity promoting F.Xa generation compared to the activity of the specific antibody (hA69-KQIhB26-PF / hAL-AQ), which comprises the H chains that consist of SEQ ID Nos: 165 and 166, and a cornu-shared L chain that consists of SEQ ID NO: 167. The multispecific antigen-binding molecule of the present invention comprises a first polypeptide and a third polypeptide that comprises an antigen-binding site that recognizes F-IX and / or F.IXa, and a second polypeptide and a fourth polypeptide that comprises an antigen-binding site 20 that recognizes FX
The first polypeptide and the third polypeptide, and the second polypeptide and the fourth polypeptide, each include the antigen binding site of the H antibody chain and the L chain antigen binding site of the antibody.
For example, in a multispecific antigen-binding molecule of the present invention, the first polypeptide and the third polypeptide include an H-chain and L-chain antigen binding site of an antibody against FIX or F.IXa , respectively; and the second polypeptide and the fourth polypeptide comprise an antigen binding site of an H chain and L chain of an antibody against FX, respectively_30 At that time, the antigen binding sites of the L chain antigen of the antibody included in the first polypeptide and in the third polypeptide, and in the second polypeptide and the fourth polypeptide can be L-chains
Shared CDTí; i.
A polypeptide comprising an L-chain antigen binding site of the antibody in the present invention is preferably a polypeptide comprising all or part of the L-chain sequence of the antibody that binds to FIX, F.IXa and F.X.
Preferred modalities of the antigen-binding site of the first polypeptide of an antibody of the present invention include, specifically, antigen-binding site comprising the amino acid sequences of: 10 Sequence of each CDR1, 2 and 3 of H chain of Q1 Sequence of each CDR1, 2 and 3 of the H chain of Q1 (SEQ ID NOs: 75, 76, and 77, respectively); Sequence of each CDR1, 2 and 3 of the H chain of Q 34 (SEQ ID NOs: 78, 79, and 80, respectively); 15 Sequence of each CDR1, 2 and 3 of the H chain of Q64 (SEQ ID NOs: 81, 82, and 83, respectively); Sequence of each Q85 H chain CDR1, 2 and 3 (SEQ ID NOs: 84, 85, and 86, respectively); Sequence of each CDR1, 2 and 3 of the 0153 H chain (SEQ ID 20 NOs: 87, 88, and 89, respectively); Sequence of each Q354 H chain CDR1, 2 and 3 (SEQ ID NOs: 90, 91, and 92, respectively); Sequence of each CDR1, 2 and 3 of the 0360 H chain (SEQ ID NOs: 93, 94, and 95, respectively); 25 Sequence of each CD40, 2 and 3 of the H chain of Q405 (SEQ ID NOs: 96, 97, and 98, respectively); Sequence of each CDR1, 2 and 3 of the H chain of Q458 (SEQ ID NOs: 99, 100, and 101, respectively); Sequence of each CDR1, 2 and 3 of the 0460 H chain (SEQ ID 30 NOs: 102, 103, and 104, respectively); and Sequence of each 0499 H chain CDR1, 2 and 3 (SEQ ID NOs: 105, 106, and 107, respectively), mentioned in the Examples described
below, or antigen-binding sites that are functionally equivalent to them.
Preferred modalities of the second polypeptide antigen binding site specifically include, for example, antigen binding sites comprising the amino acid sequences of: Sequence of each CDR1, 2 and 3 of the J232 H chain (SEQ ID NOs: 108, 109, and 110, respectively); Sequence of each J259 H chain CDR1, 2 and 3 (SEQ ID 10 NOs: 111, 112, and 113, respectively); Sequence of each J268 H chain CDR1, 2 and 3 (SEQ ID NOs: 114, 115, and 116, respectively); Sequence of each J300 H chain CDR1, 2 and 3 (SEQ ID NOs: 117, 118, and 119, respectively); 15 Sequence of each J321 H chain CDR1, 2 and 3 (SEQ ID NOs: 120, 121, and 122, respectively); Sequence of each J326 H chain CDR1, 2 and 3 (SEQ ID NOs: 123, 124, and 125, respectively); Sequence of each J327 H chain CDR1, 2 and 3 (SEQ ID 20 NOs: 126, 127, and 128, respectively); Sequence of each J339 H chain CDR1, 2 and 3 (SEQ ID NOs: 129, 130, and 131, respectively); Sequence of each J344 H chain CDR1, 2 and 3 (SEQ ID NOs: 132, 133, and 134, respectively); 25 Sequence of each J346 H chain CDR1, 2 and 3 (SEQ ID NOs: 135, 136, and 137, respectively); and Sequence of each J142 H chain CDR1, 2 and 3 (SEQ ID NOs: 174, 175, and 176, respectively), mentioned in the Examples described below, or antigen binding sites that are functionally equivalent to them . More specifically, the present invention provides multispecific antigen-binding molecules, wherein the antisera-binding site
The first polypeptide genus comprises an antigen binding site comprising H chain CDRs consisting of any of the amino acid sequences selected from the following (a1) to (all), or an antigen binding site functionally equivalent to these, and the antigen binding site of the second polypeptide comprises an antigen binding site which comprises H chain CDRs consisting of any of the sequences selected from the following (b1) to (b11), or an antigen site functionally equivalent to these : (a1) an antigen binding site comprising a CDR 1, 10 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 75, 76, and 77 (H chain CDRs of Q1), respectively; (a2) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 78, 79, and 80 (H chain CDRs of Q31), respectively; 15 (a3) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 81, 82, and 83 (H chain CDRs of Q64), respectively; (a4) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 84, 85, and 86 20 (H chain CDRs of Q85), respectively; (a5) an antigen binding site comprising CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 87, 88, and 89 (H chain CDRs of Q153), respectively; (a6) an antigen binding site comprising a CDR 1, 25 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: SEQ ID NOs: 90, 91, and 92 (H chain CDRs of Q354), respectively ; (a7) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 93, 94, and 95 (H chain CDRs of Q360), respectively; 30 (a8) an antigen-binding site comprising CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: (H chain CDRs of Q405), respectively;
(a9) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 99, 100, and 101 (H chain CDRs of Q458), respectively; (a10) an antigen binding site comprising a CDR 5 1, 2, and 3 of the H chain of amino acid sequences SEQ iD NOs: 102, 103, and 104 (H chain CDRs of Q460), respectively; (a11) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 105, 106, and 107 (H chain CDRs of Q499), respectively; 10 (b1) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 108, 109, and 110 (JR32 H chain CDRs), respectively; (b2) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: SEQ ID 15 NOs: 111, 112, and 113 (J259 H chain CDRs), respectively ; (b3) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 114, 115, and 116 (J268 H chain CDRs), respectively; (b4) an antigen binding site comprising a CDR 1, 20 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 117, 118, and 119 (J300 H chain CDRs), respectively; (b5) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 120, 121, and 122 (J321 H chain CDRs), respectively; 25 (b6) an antigen binding site comprising CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 123, 124, and 125 (J326 H chain CDRs), respectively; (b7) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 126, 127, and 30 128 (J327 H chain CDRs), respectively; (b8) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 129, 130, and
131 (J339 H chain CDRs), respectively; (b9) an antigen-binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 32, 133, and 134 (J344 H chain CDRs), respectively; 5 (b10) an antigen-binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 135, 136, and 137 (J346 H chain CDRs), respectively; and (b11) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 174, 175, 10, and 176 (J chain of CD14s of J142), respectively.
Preferred modalities of the third and fourth polypeptide antigen-binding site specifically include, for example, antigen-binding sites that comprise the sequences of: Sequence of each CDR1, 2 and 3 of the L2 H chain (SEQ iD 15 NOs: 138, 139, and 140, respectively); Sequence of each CDR1, 2 and 3 of the L45 H chain (SEQ ID NOs: 141, 142, and 143, respectively); Sequence of each L248 H chain CDR1, 2 and 3 (SEQ ID NOs: 144, 145, and 146, respectively); 20 Sequence of each CDR1, 2 and 3 of the L324 H chain (SEQ ID NOs: 147, 148, and 149, respectively); Sequence of each L334 H chain CDR1, 2 and 3 (SEQ ID NOs: 150, 151, and 152, respectively); Sequence of each L377 H chain CDR1, 2 and 3 (SEQ ID 25 NOs: 153, 154, and 155, respectively); Sequence of each L404 H chain CDR1, 2 and 3 (SEQ ID NOs: 156, 157, and 158, respectively); Sequence of each L406 H chain CDR1, 2 and 3 (SEQ ID NOs: 159, 160, and 161, respectively); 30 Sequence of each L408 H chain CDR1, 2 and 3 (SEQ ID NOs: 162, 163, and 164, respectively); and Sequence of each L180 H chain CDR1, 2 and 3 (SEQ ID
NOs: 177, 178, and 179, respectively), mentioned in the Examples described below, or antigen binding sites that are functionally equivalent to them.
More specifically, the present invention provides multispecific antigen-binding molecules, wherein the antigen-binding sites included in the third polypeptide and the fourth polypeptide comprise an antigen-binding site that comprises L-chain CDRs which consist of any of the selected amino acid sequences from the following (c1) to (cl), or an antigen-binding site functionally equivalent to these: (cl) an antigen-binding site comprising a CDR1, 2, and 3 the L chain of amino acid sequences of SEQ ID NOs: 138, 139, and 140 (LR CD L chain), respectively; (c2) an antigen binding site comprising a CDR1, 15 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 141, 142, and 143 (CDR of the L45 L chain), respectively; (c3) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 144, 145, and 146 (L chain CDR of L248), respectively; 20 (c4) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 147, 148, and 149 (CDR of the L324 L chain), respectively; (c5) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 150, 151, 25 and 152 (LR CD4 of L334), respectively; (c6) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 153, 154, and 155 (L377 L chain CDR), respectively; (c7) an antigen binding site comprising a CDRI, 30 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 156, 157, and 158 (L chain CDR of L404), respectively; (c8) an antigen binding site comprising a CDR1,
tiIYM
2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 159, 160, and 161 (L406 L chain CDR), respectively; (c9) an antigen-binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 137, 138, 5 and 139 (L chain CDR of L408), respectively; and (c10) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 177, 178, and 179 (CDR of the L180 L chain), respectively; The amino acid chains of the H 10 chain variable regions of IQ, Q31, Q64, Q85, 0153, 0354, 0360, Q405, Q458, 0460, and Q499 of the present invention are indicated by the following SEQ ID NOs, respectively: Q1: SEQIDNO: 35 Q31: SEQ ID NO: 36 15 064: SEQ ID NO: 37 Q85: SEQ ID NO: 38 Q153: SEQ ID NO: 39 Q354: SEQ ID NO: 40 Q360: SEQ ID NO: 41 20 Q405 : SEQ ID NO: 42 Q458: SEQ ID NO: 43 Q460: SEQ ID NO: 44 Q499: SEQ ID NO: 45 The amino acid sequences of the variable regions of the 25 H chain of J232, J259, J268, J300, J321, J326 , J327, J339, J344, J346, and J142 of the present invention are indicated by the following SEQ ID NOs.
Respectively: J232: SEQ ID NO: 46 J259: SEQ ID NO: 47 30 J268: SEQ ID NO: 48 J300: SEQ ID NO: 49 J321: SEQ ID NO: 50
J326: SEQ ID NO: 51 J327: SEQ ID NO: 52 J339: SEQ ID NO: 53 J344: SEQ ID NO: 54 5 J346: SEQ ID NO: 55 J142: SEQ ID NO: 172 More specifically, the present invention provides multispecific antigen-binding molecules, and that the antigen-binding site of the first polypeptide comprises an antigen-binding site that comprises a variable region of the H chain that consists of any of the selected amino acid sequences of the following (a 1) to (ai 1), or an antigen binding site functionally equivalent to these, the second antigen binding site of the second polypeptide comprises an antigen binding site comprising a variable region of the H chain 15 consisting of any of the amino acid sequences of the following (a1) to (b11), or an antigen binding site functionally equivalent to these: (a1) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 75, 76, and 77 20 (Q1 H chain CDRs), respectively; (a2) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 78, 79, and 80 (H chain CDRs of Q31), respectively; (a3) an antigen binding site comprising a CDR 1, 25 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 81, 82, and 83 (H chain CDRs of 064), respectively; (a4) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 84, 85, and 86 (H chain CDRs of Q85), respectively; 30 (a5) an antigen binding site comprising CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 87, 88, and 89 (H chain CDRs of Q153), respectively;
(a6) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: SEQ ID NOs: 90, 91, and 92 (Q354 H chain CDRs), respectively; (a7) an antigen binding site comprising a CDR 1, 5 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 93, 94, and 95 (H chain CDRs of Q360), respectively; (a8) an antigen binding site comprising CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: (H chain CDRs of Q405), respectively; 10 (a9) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 99, 100, and 101 (H chain CDRs of Q458), respectively; (a10) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 102, 103, 15 and 104 (H chain CDRs of Q460), respectively; (a11) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 105, 106, and 107 (H chain CDRs of Q499), respectively; (b1) an antigen binding site comprising a CDR 1, 20 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 108, 109, and 110 (J232 H chain CDRs), respectively; (b2) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: SEQ ID NOs: 111, 112, and 113 (J259 H chain CDRs), respectively; (B3) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 114, 115, and 116 (J268 H chain CDRs), respectively; (b4) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 117, 118, and 30 119 (J300 H chain CDRs), respectively; (b5) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 120, 121, and
122 (J321 H chain CDRs), respectively; (b6) an antigen binding site comprising CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 123, 124, and 125 (J326 H chain CDRs), respectively; 5 (b7) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 126, 127, and 128 (J327 H chain CDRs), respectively; (b8) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 129, 130, and 10 131 (H chain CDRs of J339), respectively; (b9) an antigen-binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 32, 133, and 134 (J344 H chain CDRs), respectively; (b10) an antigen binding site comprising a CDR 15 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 135, 136, and 137 (H chain CDRs of J346), respectively; and (b11) an antigen binding site comprising a CDR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 174, 175, and 176 (H chain CDRs of J142), respectively. In addition, the amino acid sequences of the variable regions of the L chain of L2, L45, L248, L324, L334, L377, L404, L406, L408, and L180 of the present invention are indicated by the following SEQ ID NOs, respectively: L2: SEQ ID NO: 56 25 L45: SEQ ID NO: 57 L248: SEQ ID NO: 58 L324: SEQ ID NO: 59 L334: SEQ ID NO: 60 L377: SEQ ID NO: 61 30 L404: SEQ ID NO: 62 L406: SEQ ID NO: 63 L408: SEQ ID NO: 64
L180: SEQ ID NO: 173 More specifically, the present invention provides multispecific antigen binding molecules, wherein the antigen binding sites included in the third polypeptide and the fourth polypeptide comprise a binding site to antigen comprising an L chain variable region consisting of any of the selected amino acid sequences from the following (cl) to (c10), or an antigen binding site functionally equivalent to these: (cl) an antigen binding site which comprises an amino acid sequence of the variable region of the L chain SEQ ID NO: 56 (variable region of the L chain of L2); (c2) an antigen binding site comprising an amino acid sequence of the variable region of the L chain SEQ ID NO: 57 (variable region of the L chain of L45); 15 (c3) an antigen-binding site comprising an amino acid sequence of the L chain variable region SEQ ID NO: 58 (L248 L chain variable region); (c4) an antigen binding site comprising an amino acid sequence of the L chain variable region SEQ ID NO: 59 (L324 L chain variable region); (c5) an antigen binding site that comprises an amino acid sequence of the L chain variable region SEQ ID NO: 60 (L334 L chain variable region); (c6) an antigen binding site comprising an amino acid sequence of the L chain variable region SEQ ID NO: 61 (L377 L chain variable region); (c7) an antigen binding site comprising an amino acid sequence of the L chain variable region SEQ ID NO: 62 (L404 L chain variable region); 30 (c8) an antigen-binding site comprising an amino acid sequence of the L chain variable region SEQ ID NO: 63 (L406 L chain variable region);
(c9) an antigen binding site comprising an amino acid sequence of the L chain variable region SEQ ID NO: 64 (L408 L chain variable region); and (c10) an antigen binding site that comprises an amino acid sequence of the L chain variable region SEQ ID NO: 173 (L180 L chain variable region). The amino acid sequences of CDR1 to 3 and FR1 to 4 in each of the sequences are as described in Figures 3A to D.
When producing life-size antibodies using the variable regions described in the present invention, without particular limitations, constant regions well known to those skilled in the art can be used.
For example, the constant regions described in "Sequences of proteins of immunological interest", (1991), U.S. can be used.
Department of Health and Human Services.
Public Health Service National 15 Institutes of Health, or "An efficient route to human bispecific IgG", (1998). Nature Biotechnology vol. 16, 677-681. Preferred examples of the antibody constant regions of the present invention include the constant regions of IgG antibodies.
When using the constant region of an IgG antibody, its type is not limited, and a constant region of the IgG subclass, 20 such as IgG1, IgG2, IgG3, or IgG4, can be used.
Amino acid mutations can be introduced, for example, those that enhance or decrease binding to Fcy receptors (Proc Natl Acad Sci US A. 2006 Mar 14; 103 (11): 4005-10; and MAbs. 2009 Nov; 1 (6): 572-9), or intensify or decrease binding to FcRn (J Biol Chem. 2001 Mar 2; 276 (9): 6591-604; 25 Int Immunol. 2006 Dec; 18 (12): 1759-69 and J Biol Chem 2006 Aug 18; 281 (33): 23514-24), but are not limited to these.
Two types of H chains must be heterologously associated to produce a bispecific antibody.
Orifice-button technology ((J immunol Methods. 2001 Feb 1; 248 (1-2): 7-15; and J Biol Chem. 2010 Jul 2; 285 (27): 20850-9), techno - 30 electrostatic repulsion technology (WO 20061106905), SEED-body technology (Protein Eng Des Sei. 2010 Apr; 23 (4): 195-202), and others can be used for the heterologous association of two types of chains H via a
CH3 domain. In addition, the antibodies of the present invention can be those with a modified or deficient sugar chain.
Examples of antibodies having modified sugar chains include glycosylation engineered antibodies (such as, WO 99154342), defucosylated sugar chain antibodies (WO 00161739, WO 02131140, WO 20061067847, WO 20061067913, etc.), and antibodies having sugar chain with bifurcation GIcNAc (such as WO 02179255). Known examples of methods for producing sugar chain-deficient IgG antibodies include the method for introducing a mutation for asparagine at position 297 at number 10 EU ((Immunol Methods. 2002 May 1; 263 (1-2): 133-47; and J Biol Chem. 2010 Jul 2; 285 (27): 20850-9) .In addition, the heterogeneity that accompanies the deletion of C-terminal lysine in IgG, and the heterogeneity that accompanies the disulfide bridging in the IgG2 hinge region can be reduced by introducing amino acid deletions / substitutions (WO 20091041613) .The present invention provides, for example, multispecific antigen binding molecules, in which the first and the second polypeptide - deos comprise an antibody H chain constant region, and the third and fourth polypeptides comprise an antibody L chain constant region.
In addition, the present invention provides multispecific antigen-binding molecules, wherein the first polypeptide comprises an antibody H chain constant region consisting of any of the amino acid sequences selected from the group consisting of the following (dl) a (d6) or the group consisting of the following (d7) to (d9), and the second polypeptide comprises an antibody H chain constant region consisting of any of the amino acid sequences selected from a group other than that of the first polypeptide mentions above: 30 (dl) a region constant of the H chain of SEQ ID NO: 65 (G4k); (d2) a H chain constant region of SEQ ID NO: 66 (z7); (d3) a H chain constant region of SEQ ID NO: 67 (z55);
(d4) a H chain constant region of SEQ ID NO: 68 (z 106); (d5) a H chain constant region of SEQ ID NO: 69 (z118); 5 (d6) a H chain constant region of SEQ ID NO: 70 (z121); (d7) a H chain constant region of SEQ ID NO: 71 (G4h); (d8) a H chain constant region of SEQ ID NO: 72 (z107); and 10 (d9) a H chain constant region of SEQ ID NO: 73 (z119). In addition, the present invention provides multispecific antigen-binding molecules, wherein the third and fourth polypeptides comprise an L chain constant region of the antibody of the following amino acid sequence of: (e) a L chain constant region SEQ ID NO: 74 (k). In the present invention, the phrase "functionally substitute F.VIll" means that F.IX and / or F.IXa, and F.X are recognized, and the activation of F.X is promoted (generation of F.Xa is promoted). 20 In the present invention, the "activity promoting the generation of F.Xa" can be confirmed by evaluating multispecific antigen-binding molecules using, for example, a measurement system comprising FIX (F-activating enzyme). IX), FIX, FX, synthetic substrate of F S-222 (synthetic substrate of F.Xa), and phospholipids.
This measurement system shows the correlation between the severity of the disease and the clinical symptoms in cases of hemophilia A (Rosen S, Andersson M, Blomba "ck M et al.
Clinical applications of a chromogenic substrate method for determination of FVIII activity.
Thromb Haemost 1985, 54: 811-23). That is, in the present measurement system, it is expected that test substances that show activity promoting the generation of higher F.Xa show better hemostatic effects against episodes in hemophilia A.
With these results, if a multispecific antigen-binding molecule with activity to functionally replace
F.VIII is a molecule that has higher activity than hA69-KQlhB26- PFlhAL-AQ, it can yield excellent blood clotting activity, and excellent effects can be obtained as a pharmaceutical component to prevent and / or treat hemorrhage, an disease that causes bleeding, or a disease caused by bleeding.
To obtain excellent effects like the pharmaceutical component mentioned above, for example, F.Xa generation promoting activity measured under the conditions described in [Example 2] is preferably not less than that of Q153-G4kIJ142-G4h / L180-k.
Here, the "F.Xa generation promoting activity" is the 10 value obtained by subtracting the change in absorbance for 20 minutes in a solvent from the change in absorbance for 20 minutes in an antibody solution.
A preferred embodiment of the present invention is a multispecific antibody that functionally substitutes F.VIII, which recognizes F.XI and 15 F.lXa, and F.X.
The multispecific antibodies mentioned above of the present invention are preferably antibodies comprising anti-F.IXIF antibody H chain CDRs. [Xa or CDRs functionally equivalent to these, anti-EX antibody H chain CDRs or CDRs. functionally 20 equivalent to these.
In addition, the antibodies of the present invention are preferably antibodies that comprise an antigen binding site having: amino acid sequences of SEQ ID NOs 75, 76, and 77 of CDR 1 1 2 and 3 (H chain CDRs of 01 ), respectively;
25 amino acid sequences of SEQ ID NOs 78, 79, and 80 of CDR 1, 2, and 3 of the H chain (CDRs of the H chain of Q31), respectively; amino acid sequences of SEQ ID NOs 81, 82, and 83 of CDR 1, 2, and 3 of the H chain (Q64 H chain CDRs), respectively; amino acid sequences of SEQ ID NOs 84, 85, and 86 of the H CDR 1, 2, and 3 of the H chain (085 H chain CDRs), respectively; amino acid sequences of SEQ ID NOs 87, 88, and 89 of CDR 1, 2, and 3 of the H chain (CD15s of the H chain of Q153), respectively;
amino acid sequences of SEQ ID NOs 90, 91, and 92 of CDR 1, 2, and 3 of the H chain (Q354 H chain CDRs), respectively; amino acid sequences of SEQ ID NOs 93, 94, and 95 of CDR 1, 2, and 3 of the H chain (Q360 H chain CDRs), respectively; 5 amino acid sequences of SEQ ID NOs 96, 97, and 98 of CDR 1, 2, and 3 of the H chain (CDRs of the H chain of Q405), respectively; amino acid sequences of SEQ ID NOs 99, 100, and 101 of CDR 1, 2, and 3 of the H chain (Q458 H chain CDRs), respectively; amino acid sequences of SEQ ID NOs 102, 103, and 104 of the 10 CDR 1, 2, and 3 of the H chain (CDRs of the H chain of 0460), respectively; or amino acid sequences of SEQ ID NOs 105, 106, and 107 of CDR 1, 2, and 3 of the H chain (Q499 H chain CDRs), respectively, in an anti-F.IXIIXa antibody or a binding site antigen 15 functionally equivalent to this, and an antigen site comprising: amino acid sequences of SEQ 1D NOs 108, 109, and 110 of CDR 1, 2, and 3 of the H chain (CDRs of the H chain of J232), respectively; amino acid sequences of SEQ ID NOs 111, 112, and 113 of the 20 CDR 1, 2, and 3 of the H chain (J259 H chain CDRs), respectively; amino acid sequences of SEQ ID NOs 114, 115, and 116 of CDR 1, 2, and 3 of the H chain (J268 H chain CDRs), respectively; amino acid sequences of SEQ ID NOs 117, 118, and 199 of CDR 1, 2, and 3 of the H chain (J300 H chain CDRs), respectively; 25 amino acid sequences of SEQ ID NOs 120, 121, and 122 of CDR 1, 2, and 3 of the H chain (J321 H chain CDRs), respectively; amino acid sequences of SEQ ID NOs 123, 124, and 125 of CDR 1, 2, and 3 of the H chain (J326 H chain CDRs), respectively; amino acid sequences of SEQ ID NOs 126, 127, and 128 of the H CDR 1, 2, and 3 of the H chain (J327 H chain CDRs), respectively; amino acid sequences of SEQ ID NOs 129, 130, and 131 of CDR 1, 2, and 3 of the H chain (J339 H chain CDRs), respectively;
amino acid sequences of SEQ ID NOs 132, 133, and 134 of CDR 1, 2, and 3 of the H chain (J334 H chain CDRs), respectively; the amino acid sequences of SEQ ID NOs 135, 136, and 137 of CDR 1, 2, and 3 of the H chain (JR6 H chain CDRs), respectively; or amino acid sequences of SEQ ID NOs 174, 175, and 176 of CDR 1, 2, and 3 of the chain (JR2 H chain CDRs), respectively, in an anti-FX antibody, or an antigen binding site and - equivalent to this. In the present invention, "antigen binding sites are functionally equivalent" means that the activities of functionally substituting F.VIII possessed by multispecific antigen binding molecules with antigen binding site are equivalent.
In the present invention, the term "equivalent" does not necessarily mean the same degree of activity, and the activity can be intensified, or the activity can be reduced as long as there is activity greater than that of hA69-KQ / hB26- PFIhAL-AQ according to the measurement system described above, or preferably the activity promoting F.Xa generation measured under the conditions described in [Example 2] is equivalent to 20 or less than Q153-G4k1J142-G4h / L180-k.
The antibodies mentioned above may have one or more amino acid substitutions, deletions, additions, and insertions in the variable region (CDR sequences and FR sequences) of the amino acid sequence provided that they have greater activity than that of hA69 -KQlhB26- 25 PFIhAL-AQ according to the measurement system described above on page 35, lines 11-30, or preferably F.X generation-promoting activity measured under the conditions described in [Example] is equivalent to or not less than that of the Q153-G4k / J142-G4h / L180-k.
A method of introducing mutations in proteins into well known to those skilled in the art as a method of introducing one or more substitutions, deletions, additions and insertions of amino acids in an amino acid sequence.
For example, those skilled in the art can prepare a desired, functionally equivalent mutant to a multispecific polypeptide multiser having the activity of functionally substituting FVIII by introducing appropriate mutations into the amino acid sequence using site-directed mutagenesis (Hashimoto-Gotoh , T, Mizuno, T, Ogasahara, Y, and Nakagawa, 5 M. (1995) An oligodeoxyribonucleotide-directed dual amber method for site- directed mutagenesis.
Gene 152: 271-275; Zoller, MJ, and Smith, M. (1983) Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors.
Methods Enzymol. 100: 468-500; Kramer, W, Drutsa, V.
Jansen, HW, Kramer, B, Pflugfelder, M, and Fritz, HJ (1984) The gapped duplex DNA appro- 10 ach to oligonucleotide-directed mutation construction.
Nucleic Acids Res. 12, 9441-9456; Kramer W, and Fritz HJ (1987) Oligonucleotide-directed constructi- on of mutations via gapped duplex DNA Methods.
Enzymol. 154: 350-367; and Kunkel, TA (1985) Rapid and efficient site-specific mutagenesis without phenotypic selection.
Proc Natl Acad Sci U S. A. 82: 488-492) and others. As such, the antibodies of the present invention may also include antibodies with one or more mutations of amino acids in the variable region, and having activity greater than that of hA69-KQ / hB26-PF / hAL-AQ according to the measurement system described above on page 35 lines 11-30, or, preferably, the activity promoting F.Xa generation under the 20 conditions described in [Example 2] is equivalent to or not less than that of Q153-G4k / J142-G4h / L180-k.
When an amino acid residue is changed, the amino acid is preferably mutated to a different amino acid that retains the properties of the amino acid side chain.
Examples of the properties of the amino acid side chain are: hydrophobic amino acids (A, 1, L, M, F, P, W, Y, and V), hydrophilic amino acids (R, D, N, C, E, Q, G , H, K, S, and T), amino acids containing aliphatic side chains (G, A, V, L, I, and P), amino acids containing side chains containing the hydroxyl group (S, T, and Y), amino acids containing sulfur-containing side chains (C and M), amino acids containing side chains containing carboxylic acid and amide (D, N, E, and Q), amino acids containing basic side acids (R, K, and H), and amino acids containing aromatic side chains (H, F, Y, and W) (amino acids are
by one-letter codes in parentheses). The amino acid substitutions within each group are called conservative substitutions.
It is already known that a polypeptide containing a modified amino acid sequence, in which one or more amino acid residues in a given sequence of amino acids are deleted, added, and replaced with other amino acids, can retain natural biological activity (Mark, D .
F. et al., Proc.
Natl.
Acad.
Sci.
USA; (1984) 81: 5662-6; Zoller, M.
J. and Smith, M., Nucleic Acids Res. (1982) 10: 6487-500; Wang, A. et al., Science (1984) 224: 1431-3; Dalbadie-McFarland, G. et al., Proc.
Natl.
Acad.
Sci.
USA 10 (1982) 79: 6409-13). Such mutants have an amino acid identity of at least 70%, more preferably at least 75%, even more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, and, most preferably at least 95% with the variable regions (e.g., CDR sequences, 15 FR sequences, and other variable regions) of the present invention.
Here, sequence identity is defined as the percentage of residues identical to those in the original amino acid sequence of the heavy chain variable region or light chain variable region, determined after the sequences are aligned and appropriate gaps are introduced to maximize the sequence identity as needed.
The identity of the amino acid sequences can be determined by the method described below.
Alternatively, the amino acid sequences of the variable regions that have a substitution, addition, and insertion of one or more amino acids in the amino acid sequence of the variable regions (CDR sequences and FR sequences), and have a greater activity that that of hA69-KQIhB26-PFIhAL-AQ according to the measurement system described above on page 35, lines 11-30, or preferably F.Xa generation promoting activity measured under the conditions described in [Example 2] is equi - valiant to or less than that of Q153-G4kIJ142-G4h / L180-k can be obtained from nucleic acids that hybridize under stringent conditions to nucleic acid composed of the nucleotide sequence that encodes the amino acid sequence of the variable regions.
Stringent hybridization conditions to isolate a nucleic acid that hybridizes under stringent conditions to a nucleic acid that includes the nucleotide sequence that encodes the amino acid sequence of the variable regions include, for example, urea conditions 6M, 0.4% SDS, 0.5 x SSC, and 37 ° C, or hybridization conditions with rigors equivalent to these.
With more vigorous conditions, for example, the conditions of 6M urea, 0.4% SDS, 0.1 x SSC, and 42 ° C, isolation of nucleic acids with much greater homology can be expected.
The sequences of the isolated nucleic acids can be determined by the known methods described below.
The homology of the total nucleotide sequences of the isolated nucleic acid is at least 50% or greater sequence identity, preferably 70% or greater, more preferably 90% or greater (e.g. 95%, 96%, 97%, 98 %, 99%, or greater). 15 Nucleic acids that hybridize under stringent conditions to a nucleic acid composed of the nucleotide sequence that encodes the amino acid sequence of the variable regions can also be isolated, instead of the methods described above using hybridization techniques, methods of gene amplification such as polymerase chain reaction (PCR) using primers synthesized based on nucleotide sequence information that encodes the amino acid sequence of the variable regions.
The identity of one amino acid sequence to another can be determined using the BLAST algorithm, by Karlin and Altschul (Proc. 25 Natl.
Acad.
Sci.
USA (1993) 90: 5873-7). Programs such as BLASTN and BLASTX were developed based on this algorithm (Altschul et al., J.
Moi.
Biol. (1990) 215: 403-10. To analyze the nucleotide sequences according to BLASTN based on BLAST, the parameters are established, for example, as score = 100 and word length = 12. On the other hand, the parameters used for the analysis of amino acid sequences - BLASTX based on BLAST include, for example, score = 50 and word length = 3. Standard parameters for each analysis are
known (see, for example, the National Center for Biotechnology Information (NCBI) website, Basic Local Alignment Search Tool (BLAST); http://www.ncbi.nlm.nih.gov). The present invention can also provide antibodies that bind to an epitope that overlaps an epitope bound by the antibodies described above.
If an antibody recognizes an epitope that overlaps with an epitope that is recognized by another antibody, it can be confirmed by competition between the two antibodies against the epitope.
The competition between the 10 antibodies can be assessed by competitive binding assays using means such as enzyme-linked immunosorbent assay (ELISA), fluorescence energy transfer method (FRET) and fluorometric microvolume assay technology (FMAT®) ). The amount of antibodies bound to an antigen correlates indirectly with the binding capacity of the candidate's 15 competing antibodies (test antibodies) that competitively bind to the overlapping epitope.
In other words, as the amount of or the affinity of the test antibodies against the overlapping epitope increases, the amount of antibodies bound to the antigen decreases, and the amount of test antibodies bound to the antigen increases.
Specifically, appropriately labeled antibodies and antibodies to be evaluated simultaneously added to the antigens, and thus bound antibodies are detected using the marker.
The amount of antibodies bound to the antigen can be easily determined by staining the antibodies beforehand.
This marker is not particularly limited, and the method of marking is selected according to the assay technique used.
The labeling method includes fluorescent labeling, radiolabeling, enzymatic labeling, and others.
For example, fluorescently labeled antibodies and non-labeled antibodies or test antibodies are added simultaneously to beads immobilized with F.IX, F.IXa or F.X, and the labeled antibodies are detected by fluorometric microvolume assay technology.
Here, the "epitope that links to the overlapping epitope" refers to
re to an antibody that can reduce the binding of the labeled antibody by at least 50% at a concentration that is usually 100 times greater, preferably 80 times greater, more preferably 50 times greater, even more preferably 30 times greater, and even more preferably 10 times 5 greater than a concentration at which the unlabeled antibody reduces the binding of the tagged antibody by 50% (IC50). Multispecific antigen-binding molecules, which have antigen-binding sites of antibodies that bind to epitopes that overlap with the epitopes linked by the antibodies mentioned above, can yield an excellent activity of functionally replacing F.VIII .
In addition, at antigen-binding sites that bind to epitopes that overlap with the epitopes linked by the antibodies mentioned above, one or more amino acids can be altered to obtain a better activity to functionally replace F.VIII.
Specific multi-antigen-binding molecules having a better activity of functionally substituting F.VIII can be obtained by altering the amino acids at antigen-binding sites and selecting multispecific antigen-binding molecules having greater activity than hA69- KQIhB26-PF / hAL-AQ according to the measurement system described above, or, preferably having activity promoting F.Xa generation measured under the conditions described above in [Example 2] which is equivalent to or not less than that of the Q153-G4k / J142-G4h / L180-k.
In order to obtain an excellent function of functionally substituting F.Vil of the present invention, the following amino acid changes are particularly preferred. 25 (1) At least one amino acid residue selected from amino acid residues at positions 34, 35, 49, 61, 62, 96, 98, 100, 100b, 102 by Kabat numbering in the H chain of the antibody recognizing F .IX and / or F.IXa is replaced with a different amino acid. (2) At least one amino acid residue selected from the 30 amino acid residues in positions 35, 53, 73, 76, 96, 98, 100, and 100a by the Kabat number of the antibody that recognizes F.
X is replaced with a different amino acid.
(3) At least one amino acid residue selected from amino acid residues at positions 27, 30, 31, 32, 50, 52, 53, 54, 55, 92, 93, 94, and 95 by Kabat numbering in the chain L of the antibody is replaced with amino acid. In addition, in the present invention, the preferred amino acids for obtaining a better functionally substituted F.VIII activity include those mentioned in (4) to (6) below.
With respect to those amino acids, the H chain of the antibody may originally have such amino acids, or the H chain amino acids may be modified to have such a sequence. (4) An H chain of the antibody that recognizes F.IX and / or F.IXa, where, by Kabat numbering, the amino acid residue at position 34 is isoleucine, the amino acid residue at position 35 is asparagine, glutamine, or serine, the amino acid residue at position 49 is serine, the amino acid residue at position 61 is arginine, the amino acid residue at position 62 15 is glutamic acid, the amino acid residue at position 96 is serine or threonine, the amino acid residue at position 98 is lysine or arginine, the amino acid residue at position 100 is phenylalanine or tyrosine, the amino acid residue at position 100b is glycine, the amino acid residue at position 102 is tyrosine. 20 (5) An H chain of the antibody that recognizes FX, where, by Kabat numbering, the amino acid residue at position 35 is aspartic acid, the amino acid residue at position 53 is arginine, the amino acid residue at position 73 is lysine, the amino acid residue at position 76 is glycine, the amino acid residue at position 96 is lysine or arginine the 25 amino acid residue at position 98 is tyrosine, the amino acid residue at position 100 is tyrosine, the amino acid residue at position 100a is histidine. (6) An L chain of the antibody, where, by kat numbering, the amino acid residue at position 27 is lysine or arginine, the amino acid residue at position 30 is glutamic acid, the amino acid residue at position 30 is arginine, the amino acid residue at position 32 is glutamine, the amino acid residue at position 50 is arginine or glutamine, the amino acid residue at position 52 is serine, the amino acid residue at position 52
• ::
is serine, the amino acid residue at position 53 is arginine, the amino acid residue at position 54 is lysine, the amino acid residue at position 55 is glutamic acid, the position of amino acid residue at position 92 is serine, the amino acid residue at position 93 is serine, the amino acid residue at position 94 is proline, the amino acid residue at position 95 is proline.
Among the amino acid residues of the antibody from (1) to (6), the favorable positions of amino acid residues to obtain an activity similar to F.VIII, particularly excellent, are shown in the following (1) to (3). 10 (1) Amino acid residues at positions 34, 35, 61, 98, 100, and 100b, particularly amino acid residues at positions 61 and 100, by Kabat numbering on the H chain of the antibody that recognizes F.IX and / or F.IXa. (2) Amino acid residues at positions 35, 53, 73, 96, 98, 15 100, and 100a by Kabat numbering in the H chain of the antibody that recognizes F.X. (3) Amino acid residues at positions 27, 30, 31, 32, 50, 52, 53, 93, 94, and 95, and, particularly, amino acid residues at positions 27, 30, 31, 50, 53, 94, and 95, by Kabat numbering on the L chain of the 20 antibody.
Specifically, the present invention provides multi-specific antigen-binding molecules, wherein the first polypeptide comprises any of the antibody H chains selected from the following (a1) to (a14) and any of the antibody L chains selected from the 25 (cl) to (c10), and the second polypeptide comprises any of the H chains selected from the following (b1) to (b12) and any of the antibody L chains selected from the following (cl) to (c10): (a1 ) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 1 (Q1-G4k); 30 (a2) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 2 (Q31-z7); (a3) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 3 (Q64-z55); (a4) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 10 (Q64-z7); (a5) an antibody H chain consisting of the 5 amino acid sequence of SEQ ID NO: 11 (Q85-G4k); (a6) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 12 (Q153-G4k); (a7) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 13 (Q354-z106); 10 (a8) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 14 (Q360-G4k); (a9) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 15 (Q360-z118); (a10) an antibody H chain consisting of the 15 amino acid sequence of SEQ ID NO: 16 (Q405-G4k); (all) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 17 (Q458-z106); (a12) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 18 (Q460-z121); 20 (a13) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 19 (Q499-z118); (a14) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 20 (Q499-zl 21); (b1) an antibody H chain consisting of the 25 amino acid sequence of SEQ ID NO: 4 (J268-G4h); (b2) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 5 (J321-G4h); (b3) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 6 (J326-z107); (B4) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 7 (J344-z107); (b5) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 21 (J232-G4h); (b6) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 22 (J259-z107); (b7) an antibody H chain consisting of the 5 amino acid sequence of SEQ ID NO: 23 (J300-z107); (b8) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 24 (J327-z107); (b9) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 25 (J327-z119); 10 (b10) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 26 (J339-z119); (b11) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 27 (J346-z107); (b12) an antibody H chain consisting of the 15 amino acid sequence of SEQ ID NO: 170 (J142-G4h); (cl) an L chain of the antibody consisting of the amino acid sequence of SEQ ID NO: 8 (L2-k); (c2) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 9 (L45-k); (C3) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 28 (L248-k); (c4) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 29 (L324-k); (c5) an antibody L chain consisting of the 25 amino acid sequence of SEQ ID NO: 30 (L334-k); (c6) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 31 (L377-k); (c7) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 32 (L404-k); (C8) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 33 (L406-k); (c9) an antibody L chain consisting of the sequence of s i:
amino acids of SEQ ID NO: 34 (L408-k); and (c10) an L chain of the antibody consisting of the amino acid sequence of SEQ ID NO: 171 (L180-k). The present invention also provides multispecific antigen-binding molecules, wherein the first polypeptide comprises an antigen-binding site that binds to an epitope that overlaps with an epitope that binds it to an antibody that consists of the H chain of the antibody of any of (a1) to (a14), and the L chain of the antibody of any of (cl) to (c10) described above, and the second polypeptide comprises an antigen binding site that binds to an an epitope that overlaps an epitope that binds to an antibody consisting of the H chain of the antibody from any of (b1) to (b12) and the L chain of any of (cl) to (c10) described above.
In addition, the present invention provides multispecific antigen-binding molecules, wherein the first polypeptide comprises any one H chain of the antibody, selected from the following (e1) to (e3), the second polypeptide comprises any one H chain of the antibody, selected from the following (f1) to (f3), and the third polypeptide and fourth polypeptide comprise any one L chain of the antibody, selected 20 from the following (g1) to g4): (e1) an H chain of an antibody that binds to an epitope that overlaps with an antibody-linked epitope consisting of an H chain of the antibody from any of (a1) to (a14) and an L chain of any of (c1) to (c10 ), of [12]; 25 (e2) an antibody H chain, in which at least one amino acid residue selected from amino acid residues at positions 34, 35, 49, 61, 62, 96, 98, 100, 100b, and 102 by Kabat numbering in any antibody H chain selected from (e1) is replaced with another amino acid; 30 (e3) an H chain of the antibody, where by the number of Kabat, the amino acid residue at position 34 is isoleucine, the amino acid residue at position 35 is asparagine, glutamine, or serine, the residue amino acid residue at position 49 is serine, the amino acid residue at position 61 is arginine, the amino acid residue at position 62 is glutamic acid, the amino acid residue at position 96 is serine or threonine, the amino acid residue in position 98 is lysine or arginine, the amino acid residue at position 100 is phenylalanine or tyrosine, the amino acid residue at position 100b is glycine, or the amino acid residue at position 102 is tyrosine in any antibody H chain selected from ( e1); (fl) an H chain of an antibody that binds to an epitope that overlaps an epitope attached by an antibody that consists of a H-layer of the antibody from either of (b1) to (b12) of [12 ] and an L chain of the antibody from either (c1) to (c10) of [12]; (f2) an antibody H chain, where at least one amino acid residue is selected from the amino acid residues at positions 35, 53, 73, 76, 96, 98, 100, and 100a by Kabat numbering on any 15 H chain the antibody of (f1) is replaced with another amino acid; (f3) an antibody H chain, in which by number, the amino acid residue at position 35 is aspartic acid, the amino acid residue at position 53 is arginine, the amino acid residue at position 73 is lysine, the amino acid residue at position 76 is glycine, amino acid residue 20 at position 96 is lysine or arginine, amino acid residue at position 76 is tyrosine, amino acid residue at position 100 is tyrosine, or amino acid residue at position 100a is histidine in any antibody H chain selected from (f1); (g 1) an L chain of an antibody that binds to an epitope that overlaps an epitope linked by an antibody that consists of an H chain of the antibody from either (a1) to (a14) and an L chain of the antibody from either (c1) to (c10), from [12]; (g2) an L chain of an antibody that binds to an epitope that overlaps with an epitope linked by an antibody that consists of an H-chain of the antibody from any of (b1) to (b12) and a chain L of the antibody of any of (c1) to (c10), of [12]; (g3) an antibody L chain, where at least one amino acid residue is selected from amino acid residues at positions 27, 30, 31, 32, 50, 52, 53, 54, 55, 92, 93, 94, and 95 by the numbering of Kabat in the L chain of the antibody or (g1) or (g2) is replaced with another amino acid; and 5 (g4) an L chain of the antibody, where by the number of Kabat, the amino acid residue at position 27 is lysine or arginine, the amino acid residue at position 30 is glutamic acid, the amino acid residue at position 31 is arginine, the amino acid residue at position 32 is glutamine, the amino acid residue at position 50 is arginine or glutamine, the 10 amino acid residue at position 52 is serine, the amino acid residue at position 53 is arginine, the amino acid residue at position 54 is lysine, the amino acid residue at position 55 is glutamic acid, the amino acid residue at position 92 is serine, the amino acid residue at position 93 is serine, the amino acid residue at position 94 is proline , or the amino acid residue at position 95 is proline, or the amino acid residue at position 95 is proline in chain L of the antibody of either (g1) or (g2). Amino acid substitutions can be performed on the antibodies (clones) of the present invention to prevent deamidation, methionine oxidation, and so on, or to structurally stabilize antibodies. The method for obtaining multi antigen binding molecules Specific to the present invention is not particularly limited, and can be any method.
Bispecific antibodies can be generated according to the methods described in WO 20061109592, WO 20061035756, WO 25 20061106905, or WO 2007111435, which are known as examples of methods for producing bispecific antibodies; and then the desired antibodies having activity that replaces the cofactor function can be selected and obtained.
For example, the bispecific antibody described in any one of the following (a) to (u) is provided by the present invention: (a) a bispecific antibody (Q1-G4k / J268-G4h / L45-k), where the first polypeptide is an H chain that consists of the amino acid sequence
nacids of SEQ ID NO: 1, the second polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 4, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO : 9; 5 (b) a bispecific antibody (Q1-G4k / J268-G4h / L45-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 1, the second polypeptide is a H chain consisting of the amino acid sequence of SEQ ID NO: 5, and the third polypeptide and the fourth polypeptide are a commonly shared L chain 10 of SEQ ID NO: 9; (c) a bispecific antibody (Q31-z7 / J326-z1071L2-k), where the first polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 2, the second polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 6, and the third polypeptide 15 and the fourth polypeptide are an L chain that are commonly shared in SEQ ID NO: 8; (d) a bispecific antibody (Q64-z551J344-zí07 / L45-k), where the first polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 3, the second peptide is an H chain that consists of 20 in the amino acid sequence of SEQ ID NO: 7, and the third polypeptide and the fourth polypeptide are an L chain of SEQ ID NO: 9; (e) a bispecific antibody (Q64-z7 / J326-z1071L334-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide is an H 25 chain consisting of in the second amino acid sequence of SEQ ID NO; 6, and the third polypeptide and the fourth polypeptide are a shared L chain of SEQ ID NO: 30; (f) a bispecific antibody (Q64-z71J344-z1071L406-k), where the first polypeptide is an H chain that consists of the 30 amino acid sequence of SEQ ID NO: 10, the second polypeptide is an H chain that consists of the sequence amino acids of SEQ ID NO: 6, and the third polypeptide and the fourth polypeptide are a commonly shared L chain
Island of SEQ ID NO: 33; (g) a bispecific antibody (Q85-G4k / J268-G4h / L406-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 11, the second polypeptide is an H 5 chain which consists of the amino acid sequence of SEQ ID NO: 4, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (h) a bispecific antibody (Q85-G4kIJ321-G4h / L334-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 11, the second polypeptide is an H chain consisting of amino acid sequence of SEQ ID NO: 5, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; (i) a bispecific antibody (Q153-G4k / J232-G4h / L406-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 12, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 21, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (J) a bispecific antibody (Q354-z1061J259-z1071L324-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 13, the second polypeptide is an H chain consisting of the sequence amino acids of SEQ ID NO: 22, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 29; (k) a bispecific antibody (Q360-G4k / J232-G4h / L406-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 14, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 21, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (I) a bispecific antibody (Q360-zl18 / J300-z107 / L334-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 15, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 23, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; (m) a bispecific antibody (Q405-G4k / J232-G4h / L248-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 16, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 21, and the third 10 polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 28; (n) a bispecific antibody (Q458-z1061J346-z1071L408-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 17, the second polypeptide is an H 15 chain consisting of the sequence amino acids of SEQ ID NO: 27, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 34; (o) a bispecific antibody (Q460-zl211J327-zl191L334-k), where the first polypeptide is an H chain consisting of the 20 amino acid sequence of SEQ ID NO: 18, the second polypeptide is an H chain consisting of the sequence amino acids of SEQ ID NO: 25, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; (p) a bispecific antibody (Q499-zl181J327-zl07 / L334-k), 25 where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 19, the second polypeptide is an H chain consisting of in the amino acid sequence of SEQ ID NO: 24, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; 30 (q) a bispecific antibody (Q499-zl18 / J327-z1071L377-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 19, the second polypeptide is an H chain consisting of in the amino acid sequence of SEQ ID NO: 24, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 31; (r) a bispecific antibody (Q499-z1181J346-z1071L248-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 19, the second polypeptide is an H chain consisting of the sequence amino acids of SEQ ID NO: 27, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 28; 10 (s) a bispecific antibody (Q499-z1211J327-G4h / L404-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 20, the second polypeptide is an H chain consisting of in the amino acid sequence of SEQ ID NO: 25, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 32; (t) a bispecific antibody (Q499-z1211J339-zl19 / L377-k), where the first polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 20, the second polypeptide is an H chain that consists of amino acid sequence of SEQ ID NO: 26, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 31; and (u) a bispecific antibody (Q153-G4k / J142-G4hIL180-k), where the first polypeptide is an H chain that consists of the 25 amino acid sequence of SEQ ID NO: 12, the second polypeptide is an H chain that it consists of the amino acid sequence of SEQ ID NO: 170, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 171; Amino acid sequences, molecular weights, isoelectric points, or the presence or absence and shape of the sugar chains of the antibodies of the present invention vary depending on the cells or hosts to produce the antibodies or purification methods described below.
However, as long as the antibodies obtained have functions equivalent to the antibodies described in the present invention, they are included in the present invention.
For example, when an antibody of the present invention is expressed in prokaryotic cells such as E. co / i, a methionine residue 5 will be added to the N-terminus of the original antibody's amino acid sequence.
The antibodies of the present invention also comprise such antibodies.
Bispecific antibodies of the present invention can be produced by methods known to those skilled in the art. 10 Based on the sequence obtained from the anti-F.IX / F.IXa antibody or anti-FX antibody, the anti-F.IXIF.IXa antibody or anti-FX antibody can be prepared, for example, by recombination techniques known to those skilled in the art.
Specifically, a polynucleotide that encodes an antibody can be constructed based on the sequence of the anti-F.IX / F.IXa antibody or the anti-FX antibody, inserted into an expression vector, and then expressed in appropriate host cells ( see, for example, Co, M.
S. et al., J.
Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, A.
H., Methods Enzymol. (1989) 178, 476-496; Pluckthun, A. and Skerra, A., Methods Enzymol. (1989) 178, 497-515; Lamoyi, E., Methods Enzy- 20 mol. (1986) 121, 652-663; Rousseaux, J. et al., Methods Enzymol. (1986) 121, 663-669; Bird, R.
E. and Walker, B.
W., Trends Biotechnol. (1991) 9, 132-137). The vectors include M13 vectors, PUC, pBR322, pBluescript, and pCR-Script vectors.
Alternatively, when the objective is to subclone and remove 25 cDNA pairs, the vectors include, for example, pGEM-T, pDIRECT, and pT7, in addition to the vectors described above.
Expression vectors are particularly useful when vectors are used to produce the antibodies of the present invention.
For example, when aiming for expression in E. coil, such as JM109, DH5a, HB101, and XL1-Blue, expression vectors not only have the characteristics that allow amplification of vectors in E. colí, but must also contain a promoter that allows for effective expression in E. coli, for example, the IacZ promoter (Ward et al., Nature (1989)
341: 544-546; FASEB J. (1992) 6: 2422-2427), araB promoter (Better etal., Science (1988) 240: 1041-1043), T7 promoter and others.
Such vectors include pGEX-5X-1 (Pharmacia), "QlAexpress system" (Qiagen), "QlAexpress system" (Qiagen), pEGFP, or pET (in this case, the host is preferably 5 t and BL21 which expresses T7 RNA polymerase) in addition to the vectors described above.
Expression plasmid vectors can contain signal sequences for antibody secretion.
With a sequence of signals for antibody secretion, a sequence of signals by B ((Lei, S.
P. et a! J. 10 Bacteriol. (1987) 169: 4379) can be used when a protein is secreted in the E. coli periplasm.
The vector can be introduced into the host cells by calcium chloride or electroporation methods, for example.
In addition to the E. co !! vectors, the vectors for producing the antibodies of the present invention include mammalian expression vectors (for example, pcDNA3 (Invitrogen), pEF-BOS (Nucleic Acids.
Res. 1990, 18 (17): p5322), pEF, and pCDM8), expression vectors derived from insect cells (for example, "the Bac-to-Bac baculovirus expression system" (Gib- BRL) and pBacPAK8), plant-derived expression vectors (for example, pMH1 and pMH2), animal virus-derived expression vectors (for example, pHSV, pMV, and pAdexLcw), retroviral expression vectors (for example, pZlPneo), yeast expression vectors (for example, "Pichia Expression Kit" (Invitrogen), pNV11, and SP-Q01), and Bacillus subtilis expression vectors (for example, PL608 and pKTH50), for example .
When expression in animal cells such as CHO, COS, and NIH3T3 cells is desired, expression plasmid vectors must have an essential promoter for expression in cells, for example, the SV40 promoter (Mulligan et al., Nature ( 1979) 277: 108), the MMLV-LTR promoter, the EF1a promoter (Mizushima et al., Nucleic Acids Res. (1990) 18: 5322), and the CMV promoter, and, more preferably, they have a gene to select transformed cells (for example, a drug resistance gene that allows evaluation using an agent (neomycin, G418, and the like). Vectors with such characteristics include pMAM, pDR2, pBK-
RSV, pBK-CMV, pOPRSV, and pOP13, for example.
In addition, the following method can be used for stable gene expression and gene amplification in cells.
CHO cells deficient in the nucleic acid synthesis pathway are introduced with a vector that contains a DHFR gene that compensates for the deficiency (for example, pSV2-dhfr (Molecular Cloning 2nd Edition, Cold Spring Harbor Laboratory Press, 1989)) , and the vector is amplified using methotrexate (MTX). Alternatively, the following method can be used for transient gene expression: COS cells with a gene that expresses the SV40 T antigen on their chromosome 10 are transformed with a vector with SV40 replication origin (pcD and others). Origins of replication derived from polyomavirus, adenovirus, bovine papillomavirus (BPV), etc., can be used as well.
To amplify the number of copies of the gene in host cells, the expression vectors may also contain selection markers such as the 15 aminoglycoside transferase gene, the thymidine kinase (TK) gene, the xanthine-guanine gene E. coli phosphoribosyltransferase (Ecogpt), and dihydrofolate reductase gene (dhfr); The antibodies of the present invention obtained by the methods described above can be isolated from within host cells or from outside host cells (the medium, or the like), and purified until they become homogeneous.
Antibodies can be isolated and purified by routine methods used to isolate and purify antibodies, and the type of method is limited.
For example, antibodies can be isolated and purified by selecting and combining column chromatography, filtration, ultrafiltration, salting-out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, polyacrylamide SDS-gel electrophoresis, tha- electrofocusing, dialysis, recrystallization, and others.
Chromatographies include, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual.
Ed Daniel R.
Marshak et al., Cold Spring Harbor Laboratory Press, 1996). The chromatographic methods described above can be conducted using liquid chromatography, for example, HPLC and FPLC.
Columns that can be used in affinity chromatography include protein columns and G protein columns.
Columns using protein A include, for example, 5 columns of protein A and columns of protein G.
In one embodiment of the antibodies of the present invention, since the antibodies of the present invention functionally replace the cofactor F.VIII, they are expected to become effective pharmaceutical agents against diseases resulting from the decrease in the activity (function) of that cofactor.
Examples of the diseases mentioned above include hemorrhage, a disease that accompanies hemorrhage, and diseases caused by hemorrhage.
In particular, there are several excellent therapeutic effects in hemophilia, where hemorrhagic disorders are caused by deficiency or a decrease in F.VIIIIF.VIIIa function.
Among hemophilia, it is expected that they will become excellent therapeutic agents for hemophilia A, in which hemorrhagic disorders are caused by hereditary deficiency or decreased F.VIII / F.Vllia function.
The present invention provides (pharmaceutical) compositions comprising the antibodies of the present invention and pharmaceutically acceptable vehicles.
For example, antibodies of the present invention that recognize both FIX or F.IXa and FX, and functionally replace F.VIII, are expected to become pharmaceutical products (pharmaceutical compositions) or pharmaceutical agents to prevent or treat hemorrhage. , diseases that accompany hemorrhage, or diseases caused by hemorrhage, and 25 similar ones.
In the context of the present invention, hemorrhage, diseases accompanying hemorrhage, or diseases caused by hemorrhage refer preferably to diseases that develop or progress due to the reduction or deficiency of F.VlII and factor VIII (F.Vllla) activity. 30 gulation activated.
Such diseases include hemophilia A described above, diseases in which an inhibitor against F.VIII / F.VIlla appears, acquired hemophilia, von Willebrand's disease and others, but are not particularly limited
, off ** i to these.
The pharmaceutical compositions used for therapeutic or preventive purposes, which comprise the present invention as active ingredients, can be formulated by mixing, if necessary, with pharmaceutically suitable vehicles, vehicles, and so that they are inactive against antibodies.
For example, sterile water, physiological saline, stabilizers, excipients, antioxidants (such as ascorbic acid), buffers (such as phosphate, citrate, histidine, and other organic acids, antiseptics, surfactants (such as PEG and Tween), chelating agents (such as EDTA), and binders can be used.
They can also comprise other low molecular weight polypeptides, proteins such as serum albumin, gelatin, and immunoglobulins, amino acids such as glycine, glutamine, asparagine, glutamic acid, methionine, arginine, and lysine, sugars and carbohydrates such as polysaccharides and monosaccharides, and 15 sugar alcohols such as mannitol and sorbitol.
When preparing an aqueous solution for injection, physiological and isotonic saline solutions comprising glucose and other adjuvants such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride can be used, and, if necessary, in combination. combination with appropriate solubilizers such as alcohol (for example, ethanol), polyalcohols (such as propylene glycol and PEG), and nonionic surfactants (such as polysorbate 80, polysorbate 20, poloxamer 188, and HCO-50) . When mixing hyaluronidase in the formulation, a larger volume of fluid can be administered simultaneously (Expert Opin Drug Deliv. 0712007; 4 (4): 427-40). If necessary, the antibodies of the present invention can be encapsulated in microcapsules (for example, those made of hydroxymethylcellulose, gelatin, and poly (methyl methacrylate) O, or incorporated as components of colloidal drug delivery systems (see, for example, microspheres of albumin, microemulsion, nanoparticles, and nano-30 capsules) (see, for example, "Remington's Pharmaceutical Science 16th Edition", Oslo Ed. (1980)). Methods for preparing pharmaceutical agents as pharmaceutical agents controlled release are also known
and such methods can be applied to the antibodies of the present invention (Langer et al., J.
Biomed.
Mater.
Res. 15: 267-277 (1981); Langer, Chemtech. 12: 98-105 (1982); US patent 3,773,919; EP Patent Application 58.481; Sidman etal., Biopolymers 22: 547-556 (1983); EP 133,988). The dose of a pharmaceutical composition of the present invention can be appropriately determined by considering the dosage form, method of administration, patient's age and body weight, patient's symptoms, type of disease, and degree of disease progression, and it is ultimately defined by clinicians.
In general, the daily dose for an adult is 0.1 mg to 10 2000 mg at one time or in several portions, even more preferably from 0.2 to 1,000 mg / day, even more preferably from 0.5 to 500 mg / day, still more preferably from 1 to 300 mg / day, even more preferably from 3 to 100 mg / day, and more preferably from 5 to 50 mg / day.
These doses may vary, depending on the patient's body weight and age, and the method of administration, however, selection of the appropriate dosage is well within the reach of those skilled in the art.
Similarly, the dosing period can be appropriately determined depending on the therapeutic progress.
In addition, the present invention provides genes or nucleic acids that encode the antibodies of the present invention.
In addition, gene therapy can be carried out by incorporating genes or nucleic acids that encode the antibodies of the present invention into vectors for gene therapy.
In addition to direct administration using "naked" plasmids, administration methods include administration after packaging in liposomes, 25 and thus forming a variety of virus vectors such as retrovirus vectors, adenovirus vectors, vaccinia virus vectors , poxviruses, vectors, adeno-associated virus vectors, and HVJ vectors (see Adolph "Viral Genome Methods" CRC Press, Florida (1996)), or coated with vehicle beads such as colloidal gold particles (WO 93117706, and others ). 30 As long as the antibodies are expressed in vivo and their activities are exercised, any method can be used for administration.
Preferably, a sufficient dose can be administered parenterally
• ::
adequate (such as intravenous, intraperitoneal, subcutaneous, intradermal, intramuscular injection or infusion, into adipose tissues or mammary glands; inhalation; bombardment with gas-driven particles (using an electron gun and the like); or nasal way as nasal drops). Alternatively, 5 the genes encoding the antibodies of the present invention can be administered to blood cells, bone marrow cells, and the like, ex vivo, using liposome transfection, particle bombardment (US Patent 4,945,050 ), or viral infection, and cells can be reintroduced into patients.
Any gene that encodes an antibody of the present invention can be used in gene therapy, and examples include genes that comprise nucleotide sequences that encode the CDRs of 01, Q31, Q64, 085, 0153, 0354, Q360, 0405, Q458, Q460, Q499, J232, J259, J268, J300, J321, J326, J327, J339, J344, J346, J142, L2, L45, L248, L324, L334, L377, L404, L406, L408, and L180 described above . The present invention also provides methods for preventing and treating hemorrhage, diseases accompanying hemorrhage, and diseases caused by hemorrhage comprising the step of administering the antibodies or compositions of the present invention.
Antibodies or compositions can be administered, for example, by the methods mentioned above.
In addition, the present invention provides kits for use with the methods mentioned above, wherein such kits comprise at least one antibody or composition of the present invention.
In addition, the kits may include a syringe, needle for injection, 25 pharmaceutically acceptable medium, alcohol-soaked cotton, adhesive bandage, package insert to describe the method of use, and the like.
The present invention also relates to the use of a multi-specific antigen-binding molecule, a bispecific antibody, or a composition of the present invention in the manufacture of an agent to prevent or treat hemorrhage, a disease accompanying hemorrhage, or a disease caused by it. by bleeding.
Additionally, the present invention relates to a molecule
1.1171.7: 3 binding to multispecific antigen, a bispecific antibody, or a composition of the present invention to prevent or treat hemorrhage, a disease accompanying a hemorrhage, or a disease caused by hemorrhage. 5 All priorities mentioned here are incorporated by reference in this specification.
Examples Here below, the present invention will be described specifically with reference to the Examples, but it is not to be interpreted as if it were limited to them.
Example 1 Production of Bispecific Antibodies Having F.Xa Generation Promoter Activity In WO 2006; 109592, hA69-KQIhB26-PF / Hal-AQ was obtained as a bispecific antibody having the function of functionally substituting 15 F.VIII.
However, there was a possibility that this antibody had an inhibitory action on the reaction in which F.IXa activates F.X using F.Vllla as cofact r.
As shown in Figure 1, antibodies that bind to F.IXIF.IXa or FX can inhibit the formation of the F.IXa-F.Vllla complex (Factor 20 Xase (F.Xase), or inhibit the activity of F-Xase (FX activation) Below, the inhibition of F.Xase formation and the action of inhibiting F.Xase activity will be referred to as F.Xase inhibitory action.
The inhibitory action of F.Xase is the inhibition of a coagulation reaction in which F.Vllla serves as the cofactor, which can suppress the function of F.VIII remaining in a patient 25 or the function of the F.VIII formulation administered .
Therefore, it is desirable that the activity promoting the generation of F.Xa, which is the objective of the bispecific antibody, is high, while the inhibitory action of F.Xase is low.
In particular, it is more desirable that the activity that promotes F.Xa generation and the inhibitory action of F.Xase are separated as much as possible. 30 However, the inhibitory action of F.Xase is due to the binding to the antigen (F.IXa and / or F.X), which is a fundamental property of the antibody.
On the other hand, a bispecific antibody having an action promoting the generation of
F.Xa (functionally replacing F.VIII) also needs to bind to antigens (F.IXa and F.X). Therefore, it is predicted that it will be extremely difficult to obtain bispecific antibodies that do not have an inhibitory action on F.Xase, but have an activity that promotes F.Xa generation (functionally substituting 5 F.VIII). Similarly, it is predicted that it will be extremely difficult to decrease the inhibitory action of F.Xase while increasing the inhibitory activity of F.Xa generation by introducing amino acid substitutions in a bispecific antibody. The present inventors have prepared genes for approximately 200 types of antibodies against human FIXa and human FX, respectively, using a method known to those skilled in the art, which is the method of obtaining antibody genes from cells producing antibodies from animals immunized with an antigen (human FIXa or human FX), and introducing amino acid substitutions when necessary. Each antibody gene was incorporated into an animal cell expression vector.
40,000 or more specific antibodies as combinations of anti-F.IXa antibody and anti-FX antibody were transiently expressed by simultaneous transfection of the human H-20 antibody H chain expression vector, the H chain expression vector of the human anti-FX antibody, and the L-chain expression vector of the antibody commonly shared in mammalian cells, such as HEK293H cells. As a comparative control, the bispecific antibody h69-KQIhB26-PF / Hal-AQ (SEQ ID NOs: 165/166/167) described in WO 20061109592 was prepared. 25 Since the mutations mentioned above in WO 20061106905 or WO 19961027011 were introduced into the CH3 domain of each H chain, it was believed that the bispecific antibodies had been mainly expressed. The antibodies in the cell culture supernatant were purified by a method known to those skilled in the art using Protein A. The present inventors measured the F.Xa-generating activity of these antibodies by the method described below. All re-
actions were performed at room temperature.
Five microliters of the antibody solution diluted with Tris-buffered saline containing 0.1% bovine serum albumin (hereinafter referred to as TBSB) was mixed with 2.5 µl of 27 nglmL.
The human factor IXa beta 5 (Enzyme Research Laboratories) and 2.5 µL of 6 IU / mL Novact® M (Kaketsuken), and then incubated in a 384-well plate, at room temperature, for 30 minutes.
The enzymatic reaction in this mixed solution was initiated by adding 5 pL of 24.7 pg / ML of Human Factor X (Enzyme Research Laboratories), and ten minutes later, 5 pL of 0.5M EDTA were added to complete the reaction.
The staining reaction was initiated by adding 5 pL of staining substrate solution.
After a 50-minute staining reaction, the change in absorbance at 405 nn was measured using SpectraMax 340PC384 (Molecular Devices). The activity promoting F.Xa generation was indicated as the value obtained by subtracting the absorbance of the antibody-free reaction solution from the absorbance of the antibody-free reaction solution.
TBCP (TBSB containing a 93.75 p phospholipid solution (SYSMEX CO.), 7.5 mM CaCl2 and 1.5 mM MgCl2) was used as solvent 20 for Human Factor IXa, Novact °) M, and Human Factor X .
A S-2222TM staining substrate solution (CHROMOGENIX) was dissolved in purified water in 1.47 mglmL, and then used in this assay.
To assess the inhibitory action of F.Xase on the antibodies, the present inventors measured the effects on the activation of F.X by F.IXa in the presence of F.Vllla using the method below.
All reactions were performed at room temperature.
Five microliters of the antibody solution diluted with Tris-buffered saline containing 0.1% bovine serum albumin (hereinafter referred to as TBSB) were mixed with 2.5 pL of 80.9 pL of 80.9 ng; mL of Human Factor IXa beta (Enzyme Research Laboratories), and then incubated in a 384-well plate at room temperature for 30 minutes.
2.5 pL of 1.8 UIImL of F.Vllla (the production method will be described later) was added, and 30 seconds later the enzymatic reaction in this mixed solution was started by adding 5 pL of 24 , 7 pg / mL Human Factor X (Enzyme Research Laboratories). Six minutes later, 5 µl of 0.5M EDTA was added to complete the reaction. The staining reaction was initiated by adding 5 pL of the staining substrate solution. After a 14 minute staining reaction, the change in absorbance at 405 nm was measured using Spectra Max 340PC384 (Molecular Devices). The inhibitory action of an antibody was indicated as the value obtained by subtracting the absorbance of the antibody-free reaction solution from the absorbance of the reaction solution supplemented with antibodies. F.Vllla was prepared by mixing 5.4 IU / mL of Kogenate ° FS (Bayer HealthCare) and 1.11 pg / mL of Human Thrombin alpha (Enzyme Rese-arch Laboratories) in a volume ratio of 1: 1, incubating at room temperature for one minute, and then adding 7.5 μl of Hirudin (Merck KgaA) in an amount that is half the volume of the mixture solution. The prepared solution was defined as 1.8 IU / mL of FVIIIa, and one minute after adding Hirudin, it was used in assays. TBCP (TBSB containing 93.75 pM phospholipid solution (SYS-20 MEX CO.), 7.5 mM CaCl2 and 1.5 mM MgCl2) was used for the solvent for Human Factor IXa, Human Factor X, Kogenate® FS, alpha Human Thrombin, and Hirudin. A S-2222TM staining substrate solution (CHROMOGE-NIX) was dissolved in purified water at 1.47 mglmL, and then used in this assay. 25 F.Xa promoting activities of each of the bispecific antibodies are indicated in Figures 3 and 4, and the inhibitory actions of F.Xase of each of the bispecific antibodies are indicated in Figure
5. Several amino acid substitutions that increase F.Xa generation promoting activity have been found, but as expected, most 30 amino acid substitutions that increase F.Xa generation promoting activity have increased F. inhibitory action. Xase too, and the inhibitory action of F.Xase was suppressed while the increase in
generation of F.Xa was very difficult.
Under such circumstances, the inventors of the present invention obtained Q1-G4k / J268-G4h / L45-k, Q1-G4k / J321-G4h / L45-k, Q31-z7 / J326- z107 / L2-k, Q64- z55 / J344-zí07 / L45-k as bispecific antibodies with high F, Xa generation promoting activity and low F.Xase inhibitory action.
In addition, Q1-G4k (SEQ ID NO: 1), Q31-z7 (SEQ ID NO: 2), and Q64-z55 (SEQ ID NO: 3) were obtained with human anti-F.IXa antibody H chains. no, J268-G4h (SEQ ID NO: 4), J321-G4h (SEQ ID NO: 5), J326-z107 (SEQ ID NO: 6), and J344-z107 (SEQ ID NO: 7) were obtained as chains H of the 10 prototype human anti-FX antibody and L2-k (SEQ ID NO: 8) and L45-k (SEQ ID NO: 9) were obtained as L chains of the prototype commonly shared antibody.
The character before the hyphen in the string name indicates the variable region and the character after the hyphen indicates the constant region.
Each bispecific antibody name is indicated by listing the sequence names of each strand to be transfected.
Most bispecific antibodies having FX-promoting activity that is close to that of hA69-KQIhB26-PF / hAL-AQ had inhibitory action as expected, but it was found that these bispecific antibodies (Q 1-G4k / J268-G4h / L45-k, Q 1-G4k1J321-G4h / L45-k, Q31-20 z7 / J326-z107 / L2-k, Q64-z55 / J344-z1071L45-k) had greater motor activity generation of F.Xa and less inhibitory action of F.Xase than the hA69-KQ / hB26-PF / hAL-AQ described in WO 20061109592. The present inventors conducted examinations to further increase the generation-promoting activity of F .X to reduce the inhibitory action of F.Xase using these four anti-bodies as prototype antibodies.
Selection of bispecific antibodies that increase the promoting activity of F.Xa generation and reduce the inhibitory action of F.Xase is shown in Figure 2. Example 2 Production of Modified Antibodies The present inventors introduced several combinations of 30 amino acid mutations that affect the activities promoting F.Xa generation and inhibitory actions of F.Xase in Example 1 for each of the prototype antibody chains by a method known to those spilled
[; 1 Y1: f]
in the technique such as PCR to introduce mutations and evaluated the combinations of chains modified on a large scale to evaluate for substitutions of amino acids that will further the production activities of F.Xa and reduce the inhibitory actions of F.Xase of the four prototype antibodies. 5 Each of the bispecific antibodies modified with amino acid substitutions was transiently expressed and purified by methods similar to those for prototype antibodies.
The activities promoting F.Xa generation of antibodies were measured using the following method.
All reactions were carried out at room temperature. 10 Five microliters of the antibody solution diluted with Tris-buffered saline containing 0.1% bovine serum albumin (hereinafter referred to as TBSB) were mixed with 2.5 µl of 27 nglmL.
Human factor IXa beta (Enzyme Research Laboratories) and 2.5 pL of 6 IU / mL Novact® M (Kaketsuken), and then incubated in a 384-well plate, 15 at room temperature, for 30 minutes.
The enzymatic reaction in this mixed solution was initiated by adding 5 pL of 24.7 pg / ML of Human Factor X (Enzyme Research Laboratories), and ten minutes later, 5 pL of 0.5M EDTA were added to complete the reaction.
The staining reaction was initiated by adding 5 pL of 20 staining substrate solution.
After a 20 minute staining reaction, the change in absorbance at 405 nn was measured using SpectraMax 340PC384 (Molecular Devices). The activity promoting F.Xa generation was indicated as the value obtained by subtracting the absorbance of the antibody-free reaction solution from the absorbance of the antibody-free reaction solution.
TBCP (TBSB containing a 93.75 p phospholipid solution (SYSMEX CO.), 7.5 mM CaCl2 and 1.5 mM MgCl2) was used as the solvent for Human Factor IXa, Novact °) M, and Human Factor X.
A S-2222® color substrate solution (CHROMOGENIX) was dissolved in purified water 30 in 1.47 mglmL, and then used in this assay.
The F.Xase inhibitory actions of the antibodies were also assessed by previously described methods.
The activities promoting F.Xa generation of each of the modified bispecific antibodies are indicated in Figure 4, and the inhibitory actions of F.Xase of each of the bispecific antibodies are indicated in Figure 5. 5 The inventors of the present invention obtained Q85 -G4k / J268- G4h / L406-k, Q85-G4k / J321-G4h / L334-k, Q64-z71J344-zl071L406-k, and Q64-z71J326-z1071L334-k as bispecific antibodies with high F-generation activity. Xa and low inhibitory action of F.Xase.
In addition, they discovered Q64-z7 (SEQ ID NO: 10) and Q85-G4k (SEQ ID NO: 11) as the H-cell of the anti-human FIXa antibody (SEQ ID NO: 30) and [406-k (SEQ ID NO: 33) as the L chains of the antibody commonly shared with increased F.Xa generation promoter activity.
Although shares have increased slightly, the activity promoting F.Xa generation has greatly increased in Q85-G4k / J268-G4h / L406-k, Q85-G4k / J321-G4h / L334-k, 15 Q64-z71J344- z07 / L406-k, and Q64-z71J326-zl071L334-k.
Since these modified antibodies have very high F.Xa promoting activities in comparison to the increase in F.Xase inhibitory actions, the promoting activity of F.Xa generation and the inhibitory action of F.Xase could be separated into compared to prototype antibodies.
Thus, the 20 combinations that suppress F.Xase's inhibitory action and increase F.Xa's promoting activity have been discovered.
Although the activity promoting F.Xa generation is preferred for prototype antibodies to functionally replace F.VIII with bispecific antibodies, the inhibitory action of F.Xase was considered favorable for clinical use in patients who maintain the functions of F.VIII or patients receiving treatment with F.VIII formulations.
Therefore, other modifications have been made to produce bispecific antibodies in which the inhibitory action of F.Xase is not increased at the same time that the promoting activity of F.Xa generation is subsequently increased. 30 As a result Q153-G4klJ232-G4h / L406-k, Q354-z1061J259- z107 / L324-k, Q360-G4k / J232-G4h / L406-k, Q360-z118 / J300-z107 / L334-k, Q405-G4k -G4h / L248-k, Q458-zl 06 / J346-zl 07 / L408-k, Q460-
z1211J327-z1191L334-k, 0499-z 118 / J327-z107 / L334-k, 0499-z 1181J 327- z 1071L377-k, Q499-z 1181J 346-z 1071L248-k, Q499-z1 21 1J 327-z 119 / L404-k, Q499-zl211J339-z119 / L377-k, and 01 53-G4k / J1 42-G4h / L1 80-k were obtained as bispecific antibodies with high promoting activity of generation of 5 F.Xa and low inhibitory action F.Xase.
In addition, the inventors found that Q153-G4k (SEQ ID NO: 12), Q354-z106 (SEQ ID NO: 13), Q360-G4k (SEQ ID NO: 14), Q360-z118 (SEQ ID NO: 15), Q405-G4k (SEQ ID NO: 16), Q458-z106 (SEQ ID NO: 17), Q460-z121 (SEQ ID NO: 18), Q499-z118 (SEQ ID NO: 19), and Q499- z121 (SEQ ID NO: 20) as the H chain of the human anti-F.IXa antibody, J232-G4h (SEQ ID NO: 21), J259-z107 (SEQ ID NO: 22), J300-z107 ( SEQ ID NO: 23), J327-z107 (SEQ ID NO: 24), J327-z119 (SEQ ID NO: 25), J339-z119 (SEQ ID NO: 26), J346-z107 (SEQ ID NO: 27) , J142-G4h (SEQ ID NO: 170) as the H chain of the human anti-FX antibody with enhanced FXa generation promoting activity, and L248-k 15 (SEQ ID NO: 28), L324-k (SEQ ID NO: 29), L377-k (SEQ ID NO: 31), L404-k (SEQ ID NO: 32), L408-k (SEQ ID NO: 34), and L180-k (SEQ ID NO: 171) as the L chains of the commonly shared antibody.
Since these antibodies have high F.Xa generation-promoting activities, while the inhibitory actions of F.Xase are suppressed, they can have very useful properties for patients who maintain high F.VIII function and patients receiving treatment with F.VIII formulations.
Since antibodies generally have long half-lives, and can be administered subcutaneously, these specific antibodies may be of great value to patients with hemophilia A, when compared to existing replacement therapy by intravenous administration of F formulations. Existing VIII for hemophilia A.
Sequence comparisons of the variable regions of each of the strands used in Example 1 and Example 2 are shown in Figures 6A to D.
For example, to enhance F.Xa generation promoting activity of a bispecific antibody, the following amino acids have been found to be important: in the H chain of the human anti-F.IXa antibody, isoleucine at position 34, asparagine, glutamine, or serine in the
dog 35, serine at position 49, arginine at position 61, glutamic acid at position 62, serine or threonine at position 96, lysine or arginine at position 98, serine or glutamic acid at position 99, phenylalanine or tyrosine at position 100, glycine at position 100, tyrosine at position 102, and others; in the H-5 of human anti-FX antibody, aspartic acid at position 35, arginine at position 53, lysine at position 73, glycine at position 76, lysine or arginine at position 96, tyrosine at position 98, tyrosine at position 100 , histidine at position 100a, and others; in the L chain of the commonly shared antibody, lysine or arginine at position 27, glutamic acid at position 30, arginine at position 10, glutamine at position 32, arginine or glutamine at position 50, serine at position 52, arginine at position 53, lysine in position 54, glutamic acid in position 55, serine in position 92, serine in position 93, proline in position 94, proline in position 95, and others (the amino acids in the variable region are numbered by the Kabat number (Kabat EA et al. 1991. Sequences of Proteins of Immunological Interest.
NIH)). Industrial Applicability The present invention provides multispecific antigen-binding molecules with a high activity of functionally replacing F.VIII, which are antibodies that recognize both the enzyme and its substrate.
In addition, the present invention provides multispecific antigen-binding molecules with a high activity of functionally replacing F.VIII and a low action of F.Xase inhibitory activity, which are antibodies that recognize both the enzyme and its substrate.
Since humanized antibodies can generally have high blood stability and low immunogenicity, the multispecific antibodies of the present invention are very promising as pharmaceutical products.

权利要求:
Claims (35)
[1]
1. Multispecific antigen-binding molecule that functionally substitutes blood coagulation factor VIII, characterized by the fact that it comprises a first antigen binding site that recognizes blood coagulation factor IX and / or blood coagulation factor IX, activated, and a second antigen-binding site that recognizes blood clotting factor X, in which the functional replacement for blood clotting factor VIII results from the activity promoting the generation of greater activated blood clotting factor X (F.Xa) that the activity of a bispecific anti-1O body (hA69-KQ / hB26-PF / hAL-AQ) comprising an H chain comprising SEQ ID NOs: 165 and 166 and a commonly shared L chain comprising SEQ ID NO : 167.
[2]
Multispecific antigen-binding molecule according to claim 1, characterized in that it comprises a first polypeptide comprising a first antigen-binding site that recognizes blood clotting factor IX and / or blood clotting factor IX , activated, and a third polypeptide comprising a third peptide binding site that recognizes blood clotting factor IX and / or activated blood clotting factor IX, as well as a second polypeptide that comprises a second site antigen binding site that recognizes blood clotting factor X and a fourth polypeptide comprising a fourth antigen binding site that recognizes blood clotting factor X.
[3]
Multispecific antigen-binding molecule according to claim 2, characterized in that the first polypeptide and the third polypeptide each comprise an antigen binding site of an H chain or L chain of an antibody against the blood clotting factor IX or blood clotting factor IX, activated, respectively; and the second and fourth polypeptides each comprise an antigen binding site of an H chain or L chain of an antibody against blood clotting factor X, respectively.
[4]
Multispecific antigen-binding molecule according to claim 3, characterized in that the antigen-binding site of the first polypeptide comprises an antigen-binding site that comprises H chain CDRs that consist of any of the amino acid sequences selected from the following (a1) to (a11), or an antigen-binding site equivalent to these, and the antigen-binding site of the second polypeptide comprises an antigen-binding site comprising CDRs of the H chain consisting of any of the selected amino acid sequences from the following (b1) to (b11), or an antigen binding site functionally equivalent to them: 1O (a1) an antigen binding site comprising a COR 1 , 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 75, 76, and 77 (01 H chain CDRs), respectively; (a2) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 78, 79, and 80 (H chain CDRs of Q31), respectively; (a3) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 81, 82, and 83 (H chain CDRs of Q64), respectively; (a4) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 84, 85, and 86 (H chain CDRs of Q85), respectively; (a5) an antigen binding site comprising COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 87, 88, and 89 (H chain CDRs of Q153), respectively; (a6) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: SEQ ID NOs: 90, 91, and 92 (Q354 H chain CDRs), respectively; (a7) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 93, 94, and 95 (H chain CDRs of Q360), respectively; (a8) an antigen binding site comprising COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: (CDRs from the
deia H of Q405), respectively; (a9) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 99, 100, and 101 (H chain CDRs of Q458), respectively; 5 (a1O) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 102, 103, and 104 (H chain Q Rs of CD460), respectively; (a11) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 105, 106, 1O and 107 (H chain CDRs of Q499), respectively; (b1) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 108, 109, and 11 O (J232 H chain CDRs), respectively; (b2) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: SEQ ID NOs: 111, 112, and 113 (J259 H chain CDRs), respectively; (b3) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 114, 115, and 116 (J268 H chain CDRs), respectively; (b4) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 117, 118, and 119 (J300 H chain CDRs), respectively; (b5) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 120, 121, and 122 (J321 H chain CDRs), respectively; (b6) an antigen binding site comprising COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 123, 124, and 125 (J326 H chain CDRs), respectively; (b7) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 126, 127, and 128 (J327 H chain CDRs), respectively; (b8) an antigen binding site comprising a COR 1,
2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 129, 130, and 131 (J339 H chain CDRs), respectively; (b9) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 132, 133, and 5 134 (J344 H chain CDRs), respectively; (b1 O) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 135, 136, and 137 (J346 H chain CDRs), respectively; and (b11 ) an antigen binding site comprising a COR 1, 2, and 3 of the H chain of amino acid sequences SEQ ID NOs: 174, 175, and 176 (JR2 H chain CDRs), respectively.
[5]
Multispecific antigen-binding molecule according to claim 3, characterized in that the antigen-binding site of the first polypeptide comprises an antigen-binding site, which comprises a variable region of the H chain consisting of any of the amino acid sequences of the following (a1) to (a11), or an antigen-binding site functionally equivalent thereto, and the antigen-binding site of the second polypeptide comprises a variable region of the H chain consisting of any of the selected amino acid sequences from the following (b1) to (b11), or an antigen binding site functionally equivalent to these: (a1) an antigen binding site comprising a variable region of the H chain of the SEQ ID sequence NO: 35 (Variable region of the H chain of 01); (a2) an antigen binding site comprising an H chain variable region of SEQ ID NO: 36 (031 H chain variable region); (a3) an antigen binding site comprising an H chain variable region of SEQ ID NO: 37 (064 H chain variable region); (a4) an antigen binding site comprising an H chain variable region of SEQ ID NO: 38 (H85 variable chain region of Q85); (a5) an antigen binding site comprising an H chain variable region of SEQ ID NO: 39 (H15 variable chain region of Q153); 5 (a6) an antigen binding site comprising an H chain variable region of SEQ ID NO: 40 (H chain variable region of Q354); (a7) an antigen binding site comprising an H chain variable region of SEQ ID NO: 41 (Q360 10 H chain variable region); (a8) an antigen binding site comprising an H chain variable region of SEQ ID NO: 42 (H chain variable region of Q405); (a9) an antigen binding site comprising an H chain variable region of SEQ ID NO: 43 (H chain variable region of Q458); (a10) an antigen binding site comprising an H chain variable region of SEQ ID NO: 44 (H chain variable region of Q460); (a11) an antigen binding site comprising an H chain variable region of SEQ ID NO: 45 (H chain variable region of Q499); (b1) an antigen binding site comprising an H chain variable region of SEQ ID NO: 46 (J232 H chain variable region); (b2) an antigen binding site comprising an H chain variable region of SEQ ID NO: 47 (J259 H chain variable region); (b3) an antigen binding site comprising an H chain variable region of SEQ ID NO: 48 (J268 H chain variable region); (b4) an antigen binding site comprising an H chain variable region of SEQ ID NO: 49 (J300 H chain variable region); (b5) an antigen binding site comprising an H chain variable region of SEQ ID NO: 50 (J321 H chain variable region); (b6) an antigen binding site comprising an H chain variable region of SEQ ID NO: 51 (J326 H chain variable region); (b7) an antigen binding site comprising an H chain variable region 10 of SEQ ID NO: 52 (J327 H chain variable region); (b8) an antigen binding site comprising an H chain variable region of SEQ ID NO: 53 (J339 H chain variable region); (b9) an antigen binding site comprising an H chain variable region of SEQ ID NO: 54 (J344 H chain variable region); (b1O) an antigen binding site comprising an H chain variable region of SEQ ID NO: 55 (J346 H chain variable region); and (b11) an antigen binding site comprising an H chain variable region of SEQ ID NO: 172 (J142 H chain variable region).
[6]
6. Multispecific antigen-binding molecule according to claim 3, characterized by the fact that the antigen-binding sites included in the third polypeptide and the fourth polypeptide comprise an antigen-binding site that comprises the chain CDRs L consisting of any of the selected amino acid sequences from the following (c1) to (c10), or an antigen binding site functionally equivalent to these: (c1) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 138, 139,
and 140 (L2 L2 chain COR), respectively; (c2) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 141, 142, and 143 (L45 COR of L45), respectively; 5 (c3) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 144, 145, and 146 (L chain L248 COR), respectively; (c4) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 147, 148, 1O and 149 (COR of the L324 L chain), respectively; (c5) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 150, 151, and 152 (L334 L chain COR), respectively; (c6) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 153, 154, and 155 (L377 L chain COR), respectively; (c7) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 156, 157, and 158 (L chain COR of L404), respectively; (c8) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 159, 160, and 161 (L chain L406 COR), respectively; (c9) an antigen binding site comprising a CDR1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 137, 138, and 139 (L chain L408 COR), respectively; and (c10 O) an antigen binding site comprising a COR 1, 2, and 3 of the L chain of amino acid sequences of SEQ ID NOs: 177, 178, and 179 (L chain COLOR of L 180), respectively.
[7]
7. Multispecific antigen-binding molecule according to claim 3, characterized in that the antigen-binding sites included in the third polypeptide and the fourth polypeptide comprise an antigen-binding site that comprises a variable region of the L chain consisting of any of the selected amino acid sequences from the following (c1) to (c10), or an antigen binding site functionally equivalent to these: (c1) an antigen binding site comprising 5 amino acid sequence the L chain variable region of SEQ ID NO: 56 (L2 variable chain region of L2); (c2) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 57 (L45 variable chain L region);
1. 1O (c3) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 58 (L248 variable chain L region); (c4) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 59 (L324 L chain variable region); (c5) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 60 (L334 variable chain L region); (c6) an antigen binding site comprising 20 amino acid sequence of the L chain variable region of SEQ ID NO: 61 (L377 L chain variable region); (c7) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 62 (L404 L chain variable region); 25 (c8) an antigen-binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 63 (L406 variable chain L region); (c9) an antigen-binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 64 (L408 L chain variable region); and (c10) an antigen binding site comprising an amino acid sequence of the L chain variable region of SEQ ID NO: 173 (L chain variable region of L 180).
[8]
8. Multispecific antigen-binding molecule according to claim 3, characterized by the fact that the first and second polypeptides further comprise a constant region of the H chain of the antibody, and the third and fourth polypeptides comprise a constant region of the L chain of the antibody.
[9]
A multispecific antigen-binding molecule according to claim 3, characterized by the fact that the first and second polypeptides comprise a constant region of the H chain of the antibody, and 10O the third and fourth polypeptides comprise a constant region of the antibody L chain, where the third and fourth polypeptides are a commonly shared L chain. 1 O. Multispecific antigen-binding molecule according to claim 8 or 9, characterized in that the first polypeptide comprises a constant region of the antibody H chain consisting of any of the amino acid sequences selected from the group that consists of the following (d1) to (d6) or the group consisting of the following (d7) to (d9), and the second polypeptide comprises an antibody constant H chain region consisting of any of the selected amino acid sequences from a group other than that of the first polypeptide mentioned above: (d1) a constant region of the H chain of SEQ ID NO: 65 (G4k); (d2) a H chain constant region of SEQ ID NO: 66 (z7); (d3) a H chain constant region of SEQ ID NO: 67 (z55); (d4) a H chain constant region of SEQ ID NO: 68 (z106); (d5) a H chain constant region of SEQ ID NO: 69 (z118); (d6) a H chain constant region of SEQ ID NO: 70 (z121); (d7) a H chain constant region of SEQ ID NO: 71 (G4h); (d8) a H chain constant region of SEQ ID NO: 72
[10]
(z107); and (d9) a H chain constant region of SEQ ID NO: 73 (z119).
[11]
A multispecific antigen-binding molecule according to claim 8 or 9, characterized in that the third and fourth polypeptides comprise the L chain constant region of the antibody consisting of the following amino acid sequence of: ( e) a L chain constant region of SEQ ID NO: 74 (k).
[12]
Multispecific antigen-binding molecule according to claim 1 or claim 8, characterized in that the first polypeptide comprises any of the antibody H chain selected from the following (a1) to (a14), the second polypeptide comprises any of the antibody H chain selected from the following (b1) to (b12), and the third polypeptide and fourth polypeptide comprise any of the antibody L chain selected from the following (c1) to (c1 O): (a1) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 1 (Q1-G4k); (a2) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 2 (Q31-z7); (a3) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 3 (Q64-z55); (a4) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 10 (Q64-z7); (a5) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 11 (Q85-G4k); (a6) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 12 (Q153-G4k); (a7) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 13 (Q354-z106); (a8) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 14 (Q360-G4k); (a9) an antibody H chain consisting of the sequence of a-
minoacids of SEQ ID NO: 15 (Q360-z118); (a10) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 16 (Q405-G4k); (a11) an antibody H chain consisting of the 5 amino acid sequence of SEQ ID NO: 17 (Q458-z106); (a12) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 18 (Q460-z121); (a13) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 19 (Q499-z118); (a14) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 20 (Q499-z121); (b1) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 4 (J268-G4h); (b2) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 5 (J321-G4h); (b3) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 6 (J326-z107); (b4) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 7 (J344-z107); (b5) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 21 (J232-G4h); (b6) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 22 (J259-z107); (b7) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 23 (J300-z107); (b8) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 24 (J327-z107); (b9) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 25 (J327-z119); (b1O) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 26 (J339-z119); (b 11) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 27 (J346-z107); (b12) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 170 (J142-G4h); (c1) an antibody L chain consisting of the a-5 minoacid sequence of SEQ ID NO: 8 (L2-k); (c2) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 9 (L45-k); (c3) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 28 (L248-k); 1O (c4) an L chain of the antibody consisting of the amino acid sequence of SEQ ID NO: 29 (L324-k); (c5) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 30 (L334-k); (c6) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 31 (L377-k); (c7) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 32 (L404-k); (c8) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 33 (L406-k); (c9) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 34 (L408-k); and (c1O) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 171 (L 180-k).
[13]
13. Multispecific antigen-binding molecule, characterized by the fact that it recognizes blood coagulation factor IX and / or activated blood coagulation factor IX, and recognizes blood coagulation factor X, in which the antigen binding of the first polypeptide comprises a second antigen binding site comprising H chain CDRs consisting of any of the amino acid sequences selected from the following (a1) to (a11), or an antigen binding site functionally equivalent to the same , the antigen-binding site of the second polypeptide comprises an antigen-binding site that comprises
end H chain CDRs consisting of any of the selected amino acid sequences from the following (b1) to (b11), or an antigen binding site functionally equivalent thereto, and the antigen binding sites included in the third and fourth polypeptides comprise an antigen binding site 5 comprising L-chain CDRs consisting of any of the amino acid sequences selected from the following (c1) to (c1 O), or an antigen binding site functionally equivalent to them: (a1) a site antigen-binding comprising 10 amino acid sequences of SEQ ID NOs: 75, 76, and 77 of COR 1, 2, and 3 of H-chain (H-chain Q1 CDRs), respectively; (a2) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 78, 79, and 80 of COR 1, 2, and 3 of H chain (H chain Q31 CDRs), respectively; (a3) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 81, 82, and 83 of COR 1, 2, and 3 of H-chain (H-chain Q34 CDRs), respectively; (a4) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 84, 85, and 86 of COR 1, 2, and 3 of H chain (H chain Q35 CDRs), respectively; (a5) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 87, 88, and 89 of COR 1, 2, and 3 of H-chain (H-chain Q153 CDRs), respectively; (a6) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 90, 91, and 92 of COR 1, 2, and 3 of H chain (H chain Q354 CDRs), respectively; (a7) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 93, 94, and 95 of COR 1, 2, and 3 of H chain (H chain Q360 CDRs), respectively; (a8) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 96, 97, and 98 of COR 1, 2, and 3 of H chain (H chain Q405 CDRs), respectively;
(a9) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 99, 100, and 101 of COR 1, 2, and 3 of H chain (CDRs of 0458 of H chain), respectively; (a1O) an antigen binding site comprising 5 amino acid sequences of SEQ ID Nos: 102, 103, and 104 of COR 1, 2, and 3 of H chain (CDRs of 0460 of H chain), respectively; . (a11) an antigen binding site comprising amino acid sequences of SEQ ID Nos: 105, 106, and 107 of COR 1, 2, and 3 of H chain (CD99s of 0499 H chain), respectively; 1O (b1) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 108, 109, and 11 O of COR 1, 2, and 3 of H chain (H2 J232 CDRs), respectively; (b2) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 111, 112, and 113 of COR 1, 2, and 3 of H chain (J259 H chain CDRs), respectively; (b3) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 114, 115, and 116 of COR 1, 2, and 3 of H chain (CD26s of H26 J268), respectively; (b4) an antigen-binding site comprising amino acid sequences of SEQ ID Nos: 117, 118, and 119 of COR 1, 2, and 3 of H chain (CD300s of H chain J300), respectively; (b5) an antigen binding site comprising amino acid sequences of SEQ ID Nos: 120, 121, and 122 of COR 1, 2, and 3 of H chain (CD32s of H chain J321), respectively; (b6) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 123, 124, and 125 of COR 1, 2, and 3 of H chain (H32 J326 CDRs), respectively; (b7) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 126, 127, and 128 of COR 1, 2, and 3 of H chain (CDRs of J327 of H chain), respectively; (b8) an antigen binding site comprising amino acid sequences of SEQ ID Nos: 129, 130, and 131 of COR 1, 2, and 3 of H chain (CDRs of J339 of H chain), respectively; (b9) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 132, 133, and 134 of COR 1, 2, and 3 of H chain (H34 J344 CDRs), respectively; 5 (b10) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 135, 136, and 137 of COR 1, 2, and 3 of H chain (CD34s of H chain J346), respectively; (b11) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 174, 175, and 176 of COR 1, 2, and 3 of 10 H chain (H chain J142 CDRs), respectively; (c1) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 138, 139, and 140 of COR 1, 2, and 3 of L chain (LR chain L2 CDRs), respectively; (c2) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 141, 142, and 143 of COR 1, 2, and 3 of L chain (CDRs of L45 L chain), respectively; (c3) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 144, 145, and 146 of COR 1, 2, and 3 of L chain (CDRs of L chain L248), respectively; (c4) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 147, 148, and 149 of COR 1, 2, and 3 of L chain (CDRs of L324 of L chain), respectively; (c5) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 150, 151, and 152 of COR 1, 2, and 3 of L chain (CDRs of L chain L334), respectively; (c6) an antigen-binding site comprising amino acid sequences of SEQ ID NOs: 153, 154, and 155 of COR 1, 2, and 3 of L chain (CDRs of L377 of L chain), respectively; (c7) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 156, 157, and 158 of COR 1, 2, and 3 of L chain (CDRs of L chain L404), respectively; (c8) an antigen-binding site comprising only two
amino acid copies of SEQ ID NOs: 159,160, and 161 of COR 1, 2, and 3 L chain (L406 L chain CDRs), respectively; (c9) an antigen-binding site comprising amino acid sequences of SEQ ID NOs: 137, 138, and 139 of COR 1, 2, and 3 of 5 L chain (L408 L chain CDRs), respectively; (c1O) an antigen binding site comprising amino acid sequences of SEQ ID NOs: 177, 178, and 179 of COR 1, 2, and 3 of L chain (CDRs of L 180 of L chain), respectively.
[14]
Multispecific antigen-binding molecule according to claim 13, characterized in that the antigen-binding site of the first polypeptide comprises an antigen-binding site comprising a variable H chain region consisting of which - either one of the selected amino acid sequences from the following (a1) to (a11), or an antigen binding site functionally equivalent to them, the antigen binding site of the second polypeptide comprises an antigen binding site comprising a region chain variable H consisting of any of the amino acid sequences selected from the following (b1) to (b11), or an antigen binding site functionally equivalent to them, and the antigen binding sites included in the third and fourth polypeptides comprise an antigen binding site comprising an L chain variable region consisting of any of the selected amino acid sequences of the following (c1) to (c1O), or an antigen-binding site functionally equivalent to them: (a1) an antigen-binding site comprising an amino acid sequence of SEQ ID NO: 35 of variable chain region H (variable region of 01 chain H); (a2) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 36 of H chain variable region (031 H chain variable region); (a3) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 37 of the H chain variable region
(variable chain Q64 of H chain); (a4) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 38 of the H chain variable region (H chain Q85 variable region); 5 (a5) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 39 of the H chain variable region (H chain Q153 variable region); (a6) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 40 of H 1O variable region (H35 Q354 variable region); (a7) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 41 of the H chain variable region (H chain Q360 variable region); (a8) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 42 of the H chain variable region (H chain Q405 variable region); (a9) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 43 of the H chain variable region (H chain Q458 variable region); (a10) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 44 of the H chain variable region (H chain Q460 variable region); (a11) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 45 of the H chain variable region (H chain Q499 variable region); (b1) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 46 of the H chain variable region (J232 H chain variable region); (b2) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 47 of the H chain variable region (J259 H chain variable region); (b3) an antigen-binding site comprising a sequence
amino acid sequence of SEQ ID NO: 48 H chain variable region (H chain J268 variable region); (b4) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 49 H 5 chain variable region (H 300 J300 variable region); (b5) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 50 of H chain variable region (H32 J321 variable region); (b6) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 51 of H chain variable region (H32 J326 variable region); (b7) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 52 of the H chain variable region (H32 J327 variable region); (b8) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 53 of H chain variable region (H chain J339 variable region); (b9) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 54 of the H chain variable region (H34 J344 variable region); (b1O) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 55 of the H chain variable region (J346 H chain variable region); (b11) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 172 of H chain variable region (H14 J142 variable region); (c1) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 56 of the L chain variable region (L2 chain variable L2 region); (c2) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 57 of L chain variable region (L45 variable chain L chain);
(c3) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 58 of L chain variable region (L248 variable chain of L chain); (c4) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 59 of the L chain variable region (L324 variable chain of the L chain); (c5) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 60 of L chain variable region (L334 variable chain of L chain); (c6) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 61 of the L chain variable region (L377 variable chain of the L chain); (c7) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 62 of the L-chain variable region (L-chain variable region L404); (c8) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 63 of L chain variable region (L chain L406 variable region); (c9) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 64 of the L chain variable region (L408 variable chain of the L chain); and (c10) an antigen binding site comprising an amino acid sequence of SEQ ID NO: 173 of variable region of L chain (variable region of L 180 of chain L).
[15]
Multispecific antigen-binding molecule according to claim 13 or 14, characterized in that the first and second polypeptides comprise an antibody H chain constant region and the third and fourth polypeptides comprise an L chain constant region of antibody.
[16]
16. Multispecific antigen-binding molecule according to claim 15, characterized by the fact that the first and second polypeptides comprise an anti-H chain constant region
The body and the third and fourth polypeptides comprise an antibody L-chain constant region and, where the third and fourth polypeptides are a commonly shared L chain.
[17]
17. Multispecific antigen-binding molecule according to claim 15 or claim 16, characterized in that the first polypeptide comprises an antibody H chain constant region consisting of any of the selected amino acid sequences of the following (d1) to (d6), or the group consisting of the following (d7) to (d9), the second polypeptide comprises a 1 H antibody chain constant region consisting of any of the amino acid sequences selected from a different group those of the first polypeptide mentioned above and the third and fourth polypeptides comprise an antibody L chain constant region consisting of the following amino acid sequence (e): (d1) a H chain constant region of SEQ ID NO: 65 (G4k); (d2) a H chain constant region of SEQ ID NO: 66 (z7); (d3) a H chain constant region of SEQ ID NO: 67 (z55); (d4) an H chain constant region of SEQ ID NO: 68 (z106); (d5) an H chain constant region of SEQ ID NO: 69 (z118); (d6) an H chain constant region of SEQ ID NO: 70 (z121); (d7) an H chain constant region of SEQ ID NO: 71 (G4h); (d8) an H chain constant region of SEQ ID NO: 72 (z107); and (d9) an H chain constant region of SEQ ID NO: 73 (z119), and (e) an L chain constant region of SEQ ID NO: 74 (k).
[18]
18. Multispecific antigen-binding molecule according to claim 15 or 16, characterized in that the first polypeptide comprises an antibody H chain of the following (a1) to (a14),
the second polypeptide comprises an antibody H chain of the following (b1) to (b12), and the third and fourth polypeptides comprise any of the antibody L chains of the following (c1) to (c1 O): (a1) a antibody H chain consisting of the 5 amino acid sequence of SEQ ID NO: 1 (Q1-G4k); (a2) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 2 (Q31-z7); (a3) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 3 (Q64-z55); 1O (a4) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 10 O (Q64-z7); (a5) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 11 (Q85-G4k); (a6) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 12 (Q153-G4k); (a7) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 13 (Q354-z106); (a8) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 14 (Q360-G4k); (a9) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 15 (Q360-z118); (a10) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 16 (Q405-G4k); (a11) an antibody H chain - consisting of the amino acid sequence of SEQ ID NO: 17 (Q458-z106); (a12) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 18 (Q460-z121); (a13) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 19 (Q499-z118); (a14) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 20 (Q499-z121); (b1) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 4 (J268-G4h); (b2) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 5 (J321-G4h); (b3) an antibody H chain consisting of the 5 amino acid sequence of SEQ ID NO: 6 (J326-z107); (b4) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 7 (J344-z107); (b5) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 21 (J232-G4h); 1O (b6) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 22 (J259-z107); (b7) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 23 (J300-z107); (b8) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 24 (J327-z107); (b9) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 25 (J327-z119); (b1O) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 26 (J339-z119); (b11) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 27 (J346-z107); (b12) an antibody H chain consisting of the amino acid sequence of SEQ ID NO: 170 (J142-G4h); (c1) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 8 (L2-k); (c2) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 9 (L45-k); (c3) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 28 (L248-k); (c4) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 29 (L324-k); (c5) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 30 (L334-k); (c6) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 31 (L377-k); (c7) an antibody L chain consisting of the 5 amino acid sequence of SEQ ID NO: 32 (L404-k); (c8) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 33 (L406-k); (c9) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 34 (L408-k); and 10O (c1O) an antibody L chain consisting of the amino acid sequence of SEQ ID NO: 171 (L180-k).
[19]
19. Multispecific antigen-binding molecule according to claim 1 or 13, characterized in that the first polypeptide comprises an antigen-binding site that binds to an epitope that overlaps with the epitope that binds an antibody consisting of the antibody H chain of any of (a1) to (a14) and the antibody L chain of any of (c1) to (c1 O), as defined in claim 12 or 18, and the second polypeptide comprises an antigen binding site that binds to an overlapping epitope that binds to an antibody that consists of the H chain of the antibody from either (b1) to (b12) and the L chain. of the antibody from either (c1) to (c1 O), as defined in claim 12 or 18.
[20]
20. Multispecific antigen-binding molecule according to claim 9, 15 or 16, characterized in that the first polypeptide comprises any one H chain of the antibody, selected from the following (e1) to (e3), the second polypeptide comprises any antibody H chain selected from the following (f1) to (f3), and the third and fourth polypeptides comprise any antibody L chain selected from the group of the following (g1) to (g4): (e1) a chain H for an antibody that binds to an epitope that overlaps an epitope linked by an antibody that consists of an H chain of the antibody from any of (a1) to (a14) and an L chain of any of ( c1) to (c10), as defined in claim 12 or 18; (e2) an antibody H chain, in which at least one amino acid residue selected from amino acid residues at positions 34, 35, 49, 61, 62, 96, 98, 100, 100b, and 102 by Kabat numbering in which - 5 or an H chain of the antibody selected from (e1) is replaced with another amino acid; (e3) an H chain of the antibody, where by the number of Kabat, the amino acid residue at position 34 is isoleucine, the amino acid residue at position 35 is asparagine, glutamine, or serine, the residue of 1The amino acid at position 49 is serine, the amino acid residue at position 61 is arginine, the amino acid residue at position 62 is glutamic acid, the amino acid residue at position 96 is serine or threonine, the amino acid residue at position 98 is lysine or arginine, the amino acid residue at position 100 is phenylalanine or tyrosine, the amino acid residue at position 1 OOb is glycine, or the amino acid residue at position 102 is tyrosine in any H chain of the antibody selected from ( e1); (f1) an H chain of an antibody that binds to an epitope that overlaps an epitope linked by an antibody that consists of an H chain of the antibody from any of (b1) to (b12) as defined in the claim 12 and an antibody L chain of any one of (c1) to (c10O) as defined in claim 12 or 18; (f2) an antibody H chain, in which at least one amino acid residue selected from the amino acid residues at positions 35, 53, 73, 76, 96, 98, 100, and 1 OOa by Kabat numbering in any H chain the antibody of (f1) is replaced with another amino acid; (f3) an H chain of the antibody, in which by the number of Kabat, the amino acid residue at position 35 is aspartic acid, the amino acid residue at position 53 is arginine, the amino acid residue at position 73 is lysine, the amino acid residue at position 96 is glycine, the amino acid residue at position 96 is lysine or arginine, the amino acid residue at position 98 is tyrosine, the amino acid residue at position 100 is tyrosine, or the amino acid residue at position 1 OOa is histidine in any antibody H chain selected from (f1); (g1) an L chain of an antibody that binds to an epitope that overlaps an epitope linked by an antibody consisting of an H chain of the antibody from either (a1) to (a14) and an L chain the antibody of any one of (c1) to (c10), as defined in claim 12 or 18; (g2) an L chain of an antibody that binds to an epitope that overlaps an epitope linked by an antibody that consists of an H chain of the antibody from either (b1) to (b12) and an L chain the anti-body of any one of (c1) to (c1O), as defined in claim 12; (g3) an antibody L chain, where at least one amino acid residue is selected from amino acid residues at positions 27, 30, 31, 32, 50, 52, 53, 54, 55, 92, 93, 94, and 95 by the numbering of Kabat in the L chain of the antibody or (g1) or (g2) is replaced with another amino acid; and (g4) an L chain of the antibody, in which by the number of Kabat, the amino acid residue at position 27 is lysine or arginine, the amino acid residue at position 30 is glutamic acid, the amino acid residue at position 31 is arginine, the amino acid residue at position 32 is glutamine, the amino acid residue at position 50 is arginine or glutamine, the amino acid residue at position 52 is serine, the amino acid residue at position 53 is arginine, the amino acid residue at position 54 is lysine, the amino acid residue at position 55 is glutamic acid, the amino acid residue at position 92 is serine, the amino acid residue at position 93 is serine, the amino acid residue at position 94 is proline, or the amino acid residue at position 95 is proline, or the amino acid residue at position 95 is proline in chain L of the antibody of either (g1) or (g2);
[21]
21. Multispecific antigen-binding molecule according to any one of claims 1 to 20, characterized in that the multispecific antigen-binding molecule is a multispecific antibody.
[22]
22. Bispecific antibody, characterized by the fact that it agrees with any of (a) to (u): (a) a bispecific antibody (Q1-G4k / J268-G4h / L45-k), in which the first polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 1, the second polypeptide is an H chain that consists of the amino acid sequence of SEQ ID NO: 4, and the third polypeptide and the fourth polypeptides are a commonly shared L chain of SEQ ID NO: 9; (b) a bispecific antibody (Q1-G4k / J268-G4h / L45-k), where 1O the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 1, the second polypeptide is a H chain consisting of the amino acid sequence of SEQ ID NO: 5, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 9; (c) a bispecific antibody (Q31-z7 / J326-z107 / L2-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 2, the second polypeptide is a chain H consisting of the amino acid sequence of SEQ ID NO: 6, and the third polypeptide and the fourth polypeptide are an L chain are commonly shared from SEQ ID NO: 8; (d) a bispecific antibody (Q64-z55 / J344-z107 / L45-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 3, the second peptide is an H chain which consists of the amino acid sequence of SEQ ID NO: 7, and the third polypeptide and the fourth polypeptide are a Lda chain SEQ ID NO: 9; (e) a bispecific antibody (Q64-z7 / J326-z107 / L334-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide is an H chain which consists of the second amino acid sequence of SEQ ID NO; 6, and the third polypeptide and the fourth polypeptide are a shared L chain of SEQ ID NO: 30; (f) a bispecific antibody (Q64-z7 / J344-z107 / L406-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 7, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (g) a bispecific antibody (Q85-G4k / J268-G4h / L406-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 11, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 4, and the third 1 The polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (h) a bispecific antibody (Q85-G4k / J321-G4h / L334-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 11, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 5, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; (i) a bispecific antibody (Q153-G4k / J232-G4h / L406-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 12, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 21, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; U) a bispecific antibody (Q354-z106 / J259-z107 / L324-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 13, the second polypeptide is an H chain consisting of in the amino acid sequence of SEQ ID NO: 22, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 29; (k) a bispecific antibody (Q360-G4k / J232-G4h / L406-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 14, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 21, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; (I) a bispecific antibody (Q360-z118 / J300-z107 / L334-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 15, the second polypeptide is an H chain which consists of the amino acid sequence of SEQ ID NO: 23, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; (m) a bispecific antibody (Q405-G4k / J232-G4h / L248-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 16, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 21, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 28; (n) a bispecific antibody (Q458-z106 / J346-z107 / L408-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 17, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 27, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 34; (o) a bispecific antibody (Q460-z121 / J327-z119 / L334-k), in which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 18, the second polypeptide is an H chain which it consists of the amino acid sequence of SEQ ID NO: 25, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; (p) a bispecific antibody (Q499-z118 / J327-z107 / L334-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 19, the second polypeptide is an H chain which consists of the amino acid sequence of SEQ ID NO: 24, and the third polypeptide and the fourth polypeptide are a commonly shared L chain
. '
r
29/31 line of SEQ ID NO: 30; (q) a bispecific antibody (Q499-z118 / J327-z107 / L377-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 19, the second polypeptide is an H 5 chain which consists of the amino acid sequence of SEQ ID NO: 24, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 31; (r) a bispecific antibody (Q499-z118 / J346-z107 / L248-k), where the first polypeptide is an H chain consisting of the 10 amino acid sequence of SEQ ID NO: 19, the second polypeptide is an H chain which consists of the amino acid sequence of SEQ ID NO: 27, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 28; (s) a bispecific antibody (Q499-z121 / J327-G4h / L404-k), out of which the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 20, the second polypeptide is an H chain which consists of the amino acid sequence of SEQ ID NO: 25, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 32; 20 (t) a bispecific antibody (Q499-z121 / J339-z119 / L377-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 20, the second polypeptide is an H chain which consists of the amino acid sequence of SEQ ID NO: 26, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 31; and (u) a bispecific antibody (Q153-G4k / J142-G4h / L 180-k), where the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 12, the second polypeptide is a chain H 30 consisting of the amino acid sequence of SEQ ID NO: 170, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 171.
,, ',. 30/31
[23]
23. Nucleic acid, characterized by the fact that it encodes the multispecific antigen-binding molecule, as defined in any of claims 1 to 21, or the bispecific antibody, as defined in claim 22. 5
[24]
24. Vector, characterized by the fact that it is inserted with the nucleic acid, as defined in claim 23.
[25]
25. Cell, characterized by the fact that it comprises nucleic acid, as defined in claim 23 or the vector, as defined in claim 24. 10
[26]
26. Method for producing the multi-specific antigen binding molecule, as defined in any of claims 1 to 21, or the bispecific antibody, as defined in claim 22, characterized by the fact that it is by culturing the cell, as defined in claim 25.
[27]
27. Pharmaceutical composition, characterized by the fact that 15 comprises the multispecific antigen-binding molecule, as defined in any one of claims 1 to 21, or the bispecific antibody, as defined in claim 22, and a pharmaceutically acceptable carrier.
[28]
28. Use of the multispecific antigen-binding molecule, as defined in any one of claims 1 to 21, the bispecific antibody, as defined in claim 22, or the composition, as defined in claim 27, characterized in that it is for the manufacture of a person for the prevention and / or treatment of hemorrhage, a disease that accompanies hemorrhage, or a disease caused by hemorrhage.
[29]
29. Use according to claim 28, characterized by the fact that hemorrhage, the disease accompanying hemorrhage, or the disease caused by hemorrhage is a disease that develops and / or progresses due to decreased or deficient activity blood clotting factor VIII and / or blood clotting factor VIII, activated.
[30]
30. Use according to claim 29, characterized by the fact that the disease that develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or coagulation factor VIII blood, activated, is hemophilia A.
I • 31/31
[31]
31. Use according to claim 29, characterized by the fact that the disease that develops and / or progresses due to a decrease or •• • • • mo or deficiency in factor VIII blood clotting and / or activity • activated blood coagulation factor VIII, is a disease that shows e-5 merger of an inhibitor against blood coagulation factor VIII and / or activated blood coagulation factor VIII.
[32]
32. Use according to claim 29, characterized by the fact that the disease that develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or 1O coagulation factor VIII activated blood is acquired hemophilia.
[33]
33. Use according to claim 29, characterized by the fact that the disease that develops and / or progresses due to a decrease or deficiency in the activity of blood coagulation factor VIII and / or blood coagulation factor VIII activated is von Willebrand's disease. 15
[34]
34. Kit for use according to use, as defined in any one of claims 28 to 33, characterized in that it comprises at least the multispecific antigen binding molecule, as defined in any one of claims 1 to 21, or the specific antibody as defined in claim 22, or the composition as defined in claim 27.
[35]
35. Invention, characterized by any forms of its actualization or in any applicable category of claim, for example, product or process or use encompassed by the material initially described, revealed or illustrated in the patent application.

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2016203564B2|2017-11-02|Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor VIII

同族专利:

---

公开号 | 公开日

---

MX355060B|2018-04-03|

---

HK1223379A1|2017-07-28|

---

US20140370018A1|2014-12-18|

---

JPWO2012067176A1|2014-05-12|

---

PT2644698T|2018-01-31|

---

KR20130102113A|2013-09-16|

---

RS57038B1|2018-05-31|

---

JP6823677B2|2021-02-03|

---

KR101398290B1|2014-05-22|

---

US10450381B2|2019-10-22|

---

KR101398363B1|2014-05-22|

---

TW201414836A|2014-04-16|

---

RU2534564C1|2014-11-27|

---

HUS1800029I1|2018-07-30|

---

MX2013005394A|2013-07-29|

---

KR20130108407A|2013-10-02|

---

LT2644698T|2018-02-26|

---

RU2620071C2|2017-05-22|

---

JP2021065233A|2021-04-30|

---

CN103298937A|2013-09-11|

---

SI2644698T1|2018-05-31|

---

RU2013118448A|2014-10-27|

---

PH12016502073A1|2018-01-29|

---

NO2644698T3|2018-06-02|

---

TWI452135B|2014-09-11|

---

KR102099580B1|2020-04-10|

---

US20160222129A1|2016-08-04|

---

AU2016203564A1|2016-06-16|

---

JP2017046697A|2017-03-09|

---

MY166429A|2018-06-26|

---

LTPA2018507I1|2018-06-25|

---

JP5246906B1|2013-07-24|

---

EP2644698B1|2018-01-03|

---

CN103298937B|2016-05-25|

---

EP3318633A1|2018-05-09|

---

KR20130102640A|2013-09-17|

---

US20170022293A1|2017-01-26|

---

JP6013915B2|2016-10-25|

---

KR20190033644A|2019-03-29|

---

JP2019129826A|2019-08-08|

---

CN105859889A|2016-08-17|

---

TR201802772T4|2018-03-21|

---

TW201631153A|2016-09-01|

---

US9334331B2|2016-05-10|

---

JP2013143942A|2013-07-25|

---

TWI452136B|2014-09-11|

---

TWI629355B|2018-07-11|

---

PL2644698T3|2018-06-29|

---

RU2534347C1|2014-11-27|

---

NL300940I2|2018-10-25|

---

LUC00076I2|2018-07-30|

---

EP2644698A4|2015-07-01|

---

DK2644698T3|2018-01-22|

---

JP6710131B2|2020-06-17|

---

TW201414835A|2014-04-16|

---

AU2011330184A1|2013-05-09|

---

US20190315884A1|2019-10-17|

---

HUE038305T2|2018-10-29|

---

HRP20180421T1|2018-04-20|

---

CA2817964A1|2012-05-24|

---

JP2013150604A|2013-08-08|

---

US20130330345A1|2013-12-12|

---

EP2644698A1|2013-10-02|

---

ES2660151T3|2018-03-21|

---

US20140037632A1|2014-02-06|

---

AU2016203564B2|2017-11-02|

---

CA2817964C|2018-06-12|

---

LTC2644698I2|2019-09-10|

---

KR101962483B1|2019-03-29|

---

JP5246905B1|2013-07-24|

---

RU2534564C3|2019-11-12|

---

CN105859889B|2020-01-07|

---

TW201243049A|2012-11-01|

---

AU2011330184B2|2016-03-10|

---

WO2012067176A1|2012-05-24|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3773919A|1969-10-23|1973-11-20|Du Pont|Polylactide-drug mixtures|

---

JPS5824836B2|1974-10-14|1983-05-24|Nohmi Bosai Kogyo Co Ltd|

---

JPS5425325B2|1976-09-12|1979-08-27|

---

US4208479A|1977-07-14|1980-06-17|Syva Company|Label modified immunoassays|

---

IE52535B1|1981-02-16|1987-12-09|Ici Plc|Continuous release pharmaceutical compositions|

---

US4474893A|1981-07-01|1984-10-02|The University of Texas System Cancer Center|Recombinant monoclonal antibodies|

---

US4444878A|1981-12-21|1984-04-24|Boston Biomedical Research Institute, Inc.|Bispecific antibody determinants|

---

JPH0228200Y2|1983-04-14|1990-07-30|

---

HUT35524A|1983-08-02|1985-07-29|Hoechst Ag|Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance|

---

DK13485A|1984-01-12|1985-07-13|Chiron Corp|HYBRIDOMA CELL LINE AND MONOCLONAL ANTIBODY OBTAINED BY A SUCH CELL LINE|

---

US4945050A|1984-11-13|1990-07-31|Cornell Research Foundation, Inc.|Method for transporting substances into living cells and tissues and apparatus therefor|

---

GB8607679D0|1986-03-27|1986-04-30|Winter G P|Recombinant dna product|

---

JPH06104071B2|1986-08-24|1994-12-21|財団法人化学及血清療法研究所|Factor IX Monoclonal antibody specific for conformation|

---

JPH0338228Y2|1986-09-26|1991-08-13|

---

US5004697A|1987-08-17|1991-04-02|Univ. Of Ca|Cationized antibodies for delivery through the blood-brain barrier|

---

US5322678A|1988-02-17|1994-06-21|Neorx Corporation|Alteration of pharmacokinetics of proteins by charge modification|

---

US6010902A|1988-04-04|2000-01-04|Bristol-Meyers Squibb Company|Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity|

---

IL89491D0|1988-11-17|1989-09-10|Hybritech Inc|Bifunctional chimeric antibodies|

---

JPH0646389Y2|1989-05-12|1994-11-30|ナショナル住宅産業株式会社|Handgrip mounting structure|

---

DE3920358A1|1989-06-22|1991-01-17|Behringwerke Ag|BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE|

---

WO1991008770A1|1989-12-11|1991-06-27|Immunomedics, Inc.|Method for antibody targeting of diagnostic or therapeutic agents|

---

US5859205A|1989-12-21|1999-01-12|Celltech Limited|Humanised antibodies|

---

EP0652950B1|1992-07-24|2007-12-19|Amgen Fremont Inc.|Generation of xenogeneic antibodies|

---

TW212184B|1990-04-02|1993-09-01|Takeda Pharm Industry Co Ltd|

---

JPH05184383A|1990-06-19|1993-07-27|Dainabotsuto Kk|Bispecific antibody|

---

JPH05199894A|1990-08-20|1993-08-10|Takeda Chem Ind Ltd|Bi-specific antibody and antibody-containing medicine|

---

CA2161351C|1993-04-26|2010-12-21|Nils Lonberg|Transgenic non-human animals capable of producing heterologous antibodies|

---

AU3328493A|1991-12-17|1993-07-19|Genpharm International, Inc.|Transgenic non-human animals capable of producing heterologous antibodies|

---

CA2089661C|1990-08-29|2007-04-03|Nils Lonberg|Transgenic non-human animals capable of producing heterologous antibodies|

---

RU2139351C1|1991-04-25|1999-10-10|Чугаи Сейяку Кабусики Кайся|H- and l-chains of monoclonal antibody pm-1 to human il-6r receptor and their v-region, modified monat, its h- and l-chains and their v-regions, cdr-sequence, dna-sequence|

---

JPH05304992A|1991-06-20|1993-11-19|Takeda Chem Ind Ltd|Hybridoma-monoclonal antibody and medicine containing antibody|

---

EP0617706B1|1991-11-25|2001-10-17|Enzon, Inc.|Multivalent antigen-binding proteins|

---

JPH0767688B2|1992-01-21|1995-07-26|近畿コンクリート工業株式会社|PC concrete panel|

---

US5667988A|1992-01-27|1997-09-16|The Scripps Research Institute|Methods for producing antibody libraries using universal or randomized immunoglobulin light chains|

---

JPH05203652A|1992-01-28|1993-08-10|Fuji Photo Film Co Ltd|Antibody enzyme immunoassay|

---

JPH05213775A|1992-02-05|1993-08-24|Otsuka Pharmaceut Co Ltd|Bfa antibody|

---

US6749853B1|1992-03-05|2004-06-15|Board Of Regents, The University Of Texas System|Combined methods and compositions for coagulation and tumor treatment|

---

PT584348E|1992-03-11|2005-10-31|Powderject Vaccines Inc|GENETIC VACCINE FOR IMMUNODEFICIENCY VIRUS|

---

US6129914A|1992-03-27|2000-10-10|Protein Design Labs, Inc.|Bispecific antibody effective to treat B-cell lymphoma and cell line|

---

US5744446A|1992-04-07|1998-04-28|Emory University|Hybrid human/animal factor VIII|

---

US5639641A|1992-09-09|1997-06-17|Immunogen Inc.|Resurfacing of rodent antibodies|

---

ZA936260B|1992-09-09|1994-03-18|Smithkline Beecham Corp|Novel antibodies for conferring passive immunity against infection by a pathogen in man|

---

JP3720353B2|1992-12-04|2005-11-24|メディカルリサーチカウンシル|Multivalent and multispecific binding proteins, their production and use|

---

CA2143126A1|1993-07-01|1995-01-12|Shamay Tang|Process for the preparation of factor x depleted plasma|

---

FR2707189B1|1993-07-09|1995-10-13|Gradient Ass|Method for treating combustion residues and installation for implementing said method.|

---

UA40577C2|1993-08-02|2001-08-15|Мерк Патент Гмбх|Bispecific antigen molecule for lysis of tumor cells, method for preparing of bispecific antigen molecule, monoclonal antibody , pharmaceutical preparation, pharmaceutical kit for lysis of tumor cells , method of lysis of tumor cells|

---

IL107742D0|1993-11-24|1994-02-27|Yeda Res & Dev|Chemically-modified binding proteins|

---

US5945311A|1994-06-03|1999-08-31|GSF--Forschungszentrumfur Umweltund Gesundheit|Method for producing heterologous bi-specific antibodies|

---

DE4419399C1|1994-06-03|1995-03-09|Gsf Forschungszentrum Umwelt|Process for the preparation of heterologous bispecific antibodies|

---

HU220347B|1994-07-11|2001-12-28|Board Of Regents The University Of Texas System|Composition for the specific coagulation of vasculature|

---

US5994524A|1994-07-13|1999-11-30|Chugai Seiyaku Kabushiki Kaisha|Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same|

---

US6309636B1|1995-09-14|2001-10-30|Cancer Research Institute Of Contra Costa|Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides|

---

PT783893E|1994-10-07|2012-05-24|Chugai Pharmaceutical Co Ltd|Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient|

---

RU2147442C1|1994-10-21|2000-04-20|Кисимото Тадамицу|Pharmaceutical composition for prophylaxis or treatment of diseases caused by il-6 formation|

---

EP0794792A1|1994-12-02|1997-09-17|Chiron Corporation|Method of promoting an immune response with a bispecific antibody|

---

US6485943B2|1995-01-17|2002-11-26|The University Of Chicago|Method for altering antibody light chain interactions|

---

AT198124T|1995-02-28|2001-01-15|Procter & Gamble|PRODUCING A CARBONIC-FREE DRINK WITH IMPROVED MICROBIAL STABILITY|

---

US5731168A|1995-03-01|1998-03-24|Genentech, Inc.|Method for making heteromultimeric polypeptides|

---

WO1996033735A1|1995-04-27|1996-10-31|Abgenix, Inc.|Human antibodies derived from immunized xenomice|

---

WO1996034096A1|1995-04-28|1996-10-31|Abgenix, Inc.|Human antibodies derived from immunized xenomice|

---

KR100259828B1|1995-09-11|2000-06-15|히라타 다다시|Antibody againsts alpha-chain of human interleukin 5 receptor|

---

MA24512A1|1996-01-17|1998-12-31|Univ Vermont And State Agrienl|PROCESS FOR THE PREPARATION OF ANTICOAGULATING AGENTS USEFUL IN THE TREATMENT OF THROMBOSIS|

---

CZ399A3|1996-07-19|1999-06-16|Amgen Inc.|Polypeptide analogs of cation-active polypeptides|

---

JPH10165184A|1996-12-16|1998-06-23|Tosoh Corp|Antibody, gene and production of chimera antibody|

---

US5990286A|1996-12-18|1999-11-23|Techniclone, Inc.|Antibodies with reduced net positive charge|

---

US6884879B1|1997-04-07|2005-04-26|Genentech, Inc.|Anti-VEGF antibodies|

---

US20070059302A1|1997-04-07|2007-03-15|Genentech, Inc.|Anti-vegf antibodies|

---

CA2288600C|1997-05-02|2010-06-01|Genentech, Inc.|A method for making multispecific antibodies having heteromultimeric and common components|

---

US20030207346A1|1997-05-02|2003-11-06|William R. Arathoon|Method for making multispecific antibodies having heteromultimeric and common components|

---

US20020062010A1|1997-05-02|2002-05-23|Genentech, Inc.|Method for making multispecific antibodies having heteromultimeric and common components|

---

DE19725586C2|1997-06-17|1999-06-24|Gsf Forschungszentrum Umwelt|Process for the preparation of cell preparations for immunization by means of heterologous intact bispecific and / or trispecific antibodies|

---

US5980893A|1997-07-17|1999-11-09|Beth Israel Deaconess Medical Center, Inc.|Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis|

---

US6207805B1|1997-07-18|2001-03-27|University Of Iowa Research Foundation|Prostate cell surface antigen-specific antibodies|

---

US6342220B1|1997-08-25|2002-01-29|Genentech, Inc.|Agonist antibodies|

---

JP3992298B2|1997-10-03|2007-10-17|中外製薬株式会社|Natural humanized antibody|

---

CN1073412C|1998-03-19|2001-10-24|中国科学院化学研究所|Method for prepn. of macromolecule microcapsule|

---

CA2325346A1|1998-04-03|1999-10-14|Chugai Seiyaku Kabushiki Kaisha|Humanized antibody against human tissue factor and process for constructing humanized antibody|

---

DK1071700T3|1998-04-20|2010-06-07|Glycart Biotechnology Ag|Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity|

---

DE19819846B4|1998-05-05|2016-11-24|Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts|Multivalent antibody constructs|

---

GB9809951D0|1998-05-08|1998-07-08|Univ Cambridge Tech|Binding molecules|

---

CA2341029A1|1998-08-17|2000-02-24|Abgenix, Inc.|Generation of modified molecules with increased serum half-lives|

---

CN1214043C|1998-12-01|2005-08-10|蛋白质设计实验室股份有限公司|Humanized antibodies to gamma-interferon|

---

US6972125B2|1999-02-12|2005-12-06|Genetics Institute, Llc|Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith|

---

EP2270147B2|1999-04-09|2020-07-22|Kyowa Kirin Co., Ltd.|Method for controlling the activity of immunologically functional molecule|

---

SK782002A3|1999-07-21|2003-08-05|Lexigen Pharm Corp|FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens|

---

EP1074842A1|1999-07-21|2001-02-07|Institut National De La Sante Et De La Recherche Medicale |Catalytic anti-factor VIII allo-antibodies|

---

NL1012907C2|1999-08-25|2001-02-27|Amb It Holding Bv|System for determining the position of a transponder.|

---

AT411997B|1999-09-14|2004-08-26|Baxter Ag|FACTOR IX / FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES|

---

SE9903895D0|1999-10-28|1999-10-28|Active Biotech Ab|Novel compounds|

---

AU1091802A|2000-10-20|2002-04-29|Chugai Pharmaceutical Co Ltd|Degraded agonist antibody|

---

WO2001075454A2|2000-04-03|2001-10-11|Oxford Glycosciences Ltd.|Diagnosis and treatment of alzheimer's disease|

---

EP1278512A2|2000-05-03|2003-01-29|MBT Munich Biotechnology AG|Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites|

---

US20020103345A1|2000-05-24|2002-08-01|Zhenping Zhu|Bispecific immunoglobulin-like antigen binding proteins and method of production|

---

US7160540B2|2000-06-30|2007-01-09|Regents Of The University Of Minnesota|Methods for detecting activity of clottings factors|

---

JP4908721B2|2000-07-17|2012-04-04|中外製薬株式会社|Screening method for ligands having physiological activity|

---

JP5291279B2|2000-09-08|2013-09-18|ウニヴェルジテート・チューリッヒ|A collection of repetitive proteins containing repetitive modules|

---

MXPA03002974A|2000-10-06|2004-05-05|Kyowa Hakko Kogyo Kk|Cells producing antibody compositions.|

---

AU2002213441B2|2000-10-12|2006-10-26|Genentech, Inc.|Reduced-viscosity concentrated protein formulations|

---

JP2004526419A|2000-10-16|2004-09-02|フィロスインク．|Protein scaffolds for antibody mimics and other binding proteins|

---

ES2727425T3|2000-12-12|2019-10-16|Medimmune Llc|Molecules with prolonged half-lives, compositions and uses thereof|

---

WO2002079255A1|2001-04-02|2002-10-10|Idec Pharmaceuticals Corporation|RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII|

---

MY138286A|2001-04-13|2009-05-29|Biogen Idec Inc|Antibodies to vla-1|

---

US20030157561A1|2001-11-19|2003-08-21|Kolkman Joost A.|Combinatorial libraries of monomer domains|

---

PT2208784E|2001-06-22|2013-04-03|Chugai Pharmaceutical Co Ltd|Cell proliferation inhibitors containing anti-glypican 3 antibody|

---

US20030049203A1|2001-08-31|2003-03-13|Elmaleh David R.|Targeted nucleic acid constructs and uses related thereto|

---

DE60232265D1|2001-10-25|2009-06-18|Genentech Inc|GLYCOPROTEIN COMPOSITIONS|

---

US20030190705A1|2001-10-29|2003-10-09|Sunol Molecular Corporation|Method of humanizing immune system molecules|

---

DE10156482A1|2001-11-12|2003-05-28|Gundram Jung|Bispecific antibody molecule|

---

US20030224397A1|2002-02-11|2003-12-04|Genentech, Inc.|Antibody variants with faster antigen association rates|

---

AU2003227504A1|2002-04-15|2003-10-27|Chugai Seiyaku Kabushiki Kaisha|METHOD OF CONSTRUCTING scDb LIBRARY|

---

AU2003235833A1|2002-04-26|2003-11-10|Chugai Seiyaku Kabushiki Kaisha|Method of screening agonistic antibody|

---

US20050130224A1|2002-05-31|2005-06-16|Celestar Lexico- Sciences, Inc.|Interaction predicting device|

---

JP2004086862A|2002-05-31|2004-03-18|Celestar Lexico-Sciences Inc|Apparatus, method and program for processing protein interaction information, and recording medium|

---

WO2003105757A2|2002-06-12|2003-12-24|Genencor International, Inc.|Methods and compositions for milieu-dependent binding of a targeted agent to a target|

---

DK2314629T3|2002-07-18|2014-01-20|Merus B V|Recombinant preparation of mixtures of antibodies|

---

AU2003264009A1|2002-08-15|2004-03-03|Epitomics, Inc.|Humanized rabbit antibodies|

---

EP1550115A2|2002-10-07|2005-07-06|Mempile Inc.|Tight focusing method and system|

---

GB0224082D0|2002-10-16|2002-11-27|Celltech R&D Ltd|Biological products|

---

WO2004060919A1|2002-12-26|2004-07-22|Chugai Seiyaku Kabushiki Kaisha|Agonist antibody against heteroreceptor|

---

US8337841B2|2003-01-21|2012-12-25|Chugai Seiyaku Kabushiki Kaisha|Methods of screening for antibody light chains|

---

JP2006517109A|2003-02-07|2006-07-20|プロテインデザインラブスインコーポレイテッド|Amphiregulin antibodies and their use to treat cancer and psoriasis|

---

GB2400851B|2003-04-25|2004-12-15|Bioinvent Int Ab|Identifying binding of a polypeptide to a polypeptide target|

---

GB2401040A|2003-04-28|2004-11-03|Chugai Pharmaceutical Co Ltd|Method for treating interleukin-6 related diseases|

---

EP2395016A3|2003-05-30|2012-12-19|Merus B.V.|Design and use of paired variable regions of specific binding molecules|

---

NZ543712A|2003-06-05|2008-06-30|Genentech Inc|Combination therapy for B cell disorders|

---

WO2004111233A1|2003-06-11|2004-12-23|Chugai Seiyaku Kabushiki Kaisha|Process for producing antibody|

---

US7297336B2|2003-09-12|2007-11-20|Baxter International Inc.|Factor IXa specific antibodies displaying factor VIIIa like activity|

---

JP2005101105A|2003-09-22|2005-04-14|Canon Inc|Positioning device, exposure apparatus, and device manufacturing method|

---

AU2003271174A1|2003-10-10|2005-04-27|Chugai Seiyaku Kabushiki Kaisha|Double specific antibodies substituting for functional protein|

---

WO2005035754A1|2003-10-14|2005-04-21|Chugai Seiyaku Kabushiki Kaisha|Double specific antibodies substituting for functional protein|

---

CA2543360A1|2003-10-24|2005-05-06|Joost A. Kolkman|Ldl receptor class a and egf domain monomers and multimers|

---

WO2005047327A2|2003-11-12|2005-05-26|Biogen Idec Ma Inc.|NEONATAL Fc RECEPTOR -BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO|

---

NZ547157A|2003-12-10|2009-07-31|Medarex Inc|Interferon Alpha Antibodies and their uses|

---

PT1691837E|2003-12-10|2012-08-27|Medarex Inc|Ip-10 antibodies and their uses|

---

WO2005062916A2|2003-12-22|2005-07-14|Centocor, Inc.|Methods for generating multimeric molecules|

---

US20050266425A1|2003-12-31|2005-12-01|Vaccinex, Inc.|Methods for producing and identifying multispecific antibodies|

---

US9328169B2|2004-01-09|2016-05-03|Pfizer Inc.|Human antibodies that bind human MAdCAM|

---

CA2561264A1|2004-03-24|2005-10-06|Xencor, Inc.|Immunoglobulin variants outside the fc region|

---

WO2005112564A2|2004-04-15|2005-12-01|The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services|Germline and sequence variants of humanized antibodies and methods of making and using them|

---

AR049390A1|2004-06-09|2006-07-26|Wyeth Corp|ANTIBODIES AGAINST HUMAN INTERLEUQUINE-13 AND USES OF THE SAME|

---

EP1773391A4|2004-06-25|2009-01-21|Medimmune Inc|Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis|

---

KR100863776B1|2004-07-15|2008-10-16|젠코어 인코포레이티드|OPTIMIZED Fc VARIANTS|

---

BRPI0515230A|2004-08-19|2008-07-15|Genentech Inc|isolated polypeptides, antibodies and nucleic acids, compositions, expression vector, isolated host cells, method of producing an antibody, manufactured articles, methods of treatment and alleviating dysfunction, methods of making and selecting a polypeptide, antibody cd20 binding agent, isolated anti-her2 antibody and uses of an antibody|

---

WO2006028936A2|2004-09-02|2006-03-16|Genentech, Inc.|Heteromultimeric molecules|

---

US20060074225A1|2004-09-14|2006-04-06|Xencor, Inc.|Monomeric immunoglobulin Fc domains|

---

WO2006030200A1|2004-09-14|2006-03-23|National Institute For Biological Standards And Control|Vaccine|

---

US7563443B2|2004-09-17|2009-07-21|Domantis Limited|Monovalent anti-CD40L antibody polypeptides and compositions thereof|

---

US7462697B2|2004-11-08|2008-12-09|Epitomics, Inc.|Methods for antibody engineering|

---

AU2005335714B2|2004-11-10|2012-07-26|Macrogenics, Inc.|Engineering Fc antibody regions to confer effector function|

---

CA2586803C|2004-12-14|2012-12-11|Ge Healthcare Bio-Sciences Ab|Purification of immunoglobulins|

---

WO2006067847A1|2004-12-22|2006-06-29|Chugai Seiyaku Kabushiki Kaisha|Method of preparing antibody by use of cell having its fucose transporter function inhibited|

---

US9493569B2|2005-03-31|2016-11-15|Chugai Seiyaku Kabushiki Kaisha|Structural isomers of sc2|

---

WO2006106905A1|2005-03-31|2006-10-12|Chugai Seiyaku Kabushiki Kaisha|Process for production of polypeptide by regulation of assembly|

---

PT1876236E|2005-04-08|2014-10-22|Chugai Pharmaceutical Co Ltd|Antibody substituting for function of blood coagulation factor viii|

---

ZA200710599B|2005-04-15|2009-08-26|Genentech Inc|HGF Beta chain variants|

---

EP2221316A1|2005-05-05|2010-08-25|Duke University|Anti-CD19 antibody therapy for autoimmune disease|

---

US8945543B2|2005-06-10|2015-02-03|Chugai Seiyaku Kabushiki Kaisha|Stabilizer for protein preparation comprising meglumine and use thereof|

---

WO2006132341A1|2005-06-10|2006-12-14|Chugai Seiyaku Kabushiki Kaisha|sc2 SITE-DIRECTED MUTANT|

---

US20070110757A1|2005-06-23|2007-05-17|Ziping Wei|Antibody formulations having optimized aggregation and fragmentation profiles|

---

US8236518B2|2005-07-15|2012-08-07|The University Of Vermont And State Agriculture College|Highly sensitive immunoassays and antibodies for detection of blood factor VIII|

---

CA2619491C|2005-08-19|2016-05-10|Wyeth|Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders|

---

WO2007060411A1|2005-11-24|2007-05-31|Ucb Pharma S.A.|Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r|

---

ES2654040T3|2006-03-31|2018-02-12|Chugai Seiyaku Kabushiki Kaisha|Antibody modification method for the purification of bispecific antibodies|

---

US11046784B2|2006-03-31|2021-06-29|Chugai Seiyaku Kabushiki Kaisha|Methods for controlling blood pharmacokinetics of antibodies|

---

ES2544888T3|2006-06-08|2015-09-04|Chugai Seiyaku Kabushiki Kaisha|Prevention or remedy for inflammatory diseases|

---

WO2007147901A1|2006-06-22|2007-12-27|Novo Nordisk A/S|Production of bispecific antibodies|

---

US20100034194A1|2006-10-11|2010-02-11|Siemens Communications Inc.|Eliminating unreachable subscribers in voice-over-ip networks|

---

JPWO2008090960A1|2007-01-24|2010-05-20|協和発酵キリン株式会社|Recombinant antibody composition that specifically binds to ganglioside GM2|

---

AU2008234248C1|2007-03-29|2015-01-22|Genmab A/S|Bispecific antibodies and methods for production thereof|

---

US20100267934A1|2007-05-31|2010-10-21|Genmab A/S|Stable igg4 antibodies|

---

AU2007358045A1|2007-08-23|2009-02-26|Lfb Biotechnologies|Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the C1 domain of factor VIII|

---

SG193868A1|2007-09-26|2013-10-30|Chugai Pharmaceutical Co Ltd|Modified antibody constant region|

---

CN101939425B|2007-09-26|2014-05-14|中外制药株式会社|Anti-IL-6 receptor antibody|

---

PL2202245T3|2007-09-26|2017-02-28|Chugai Seiyaku Kabushiki Kaisha|Method of modifying isoelectric point of antibody via amino acid substitution in cdr|

---

AU2008305851B2|2007-09-28|2014-12-18|Chugai Seiyaku Kabushiki Kaisha|Anti-glypican-3 antibody having improved kinetics in plasma|

---

PE20091174A1|2007-12-27|2009-08-03|Chugai Pharmaceutical Co Ltd|LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT|

---

ES2563027T3|2008-01-07|2016-03-10|Amgen Inc.|Method for manufacturing antibody Fc heterodimer molecules using electrostatic conduction effects|

---

NZ717429A|2008-04-11|2018-07-27|Chugai Pharmaceutical Co Ltd|Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly|

---

MX2010011717A|2008-05-01|2010-11-30|Amgen Inc|Anti-hepcidin antibodies and methods of use.|

---

TWI440469B|2008-09-26|2014-06-11|Chugai Pharmaceutical Co Ltd|Improved antibody molecules|

---

US20120071634A1|2009-03-19|2012-03-22|Chugai Seiyaku Kabushiki Kaisha|Antibody Constant Region Variant|

---

EP2233500A1|2009-03-20|2010-09-29|LFB Biotechnologies|Optimized Fc variants|

---

EP2417156B1|2009-04-07|2015-02-11|Roche Glycart AG|Trivalent, bispecific antibodies|

---

AU2010245011B2|2009-04-27|2015-09-03|Oncomed Pharmaceuticals, Inc.|Method for making heteromultimeric molecules|

---

CN101906160A|2009-06-05|2010-12-08|苏州泽璟生物制药有限公司|Human blood coagulation factor VIII resisting monoclonal antibody as well as preparation method and application thereof|

---

WO2011157283A1|2010-06-14|2011-12-22|Paion Deutschland Gmbh|Treatment of coagulopathy with hyperfibrinolysis|

---

KR101904065B1|2009-06-26|2018-10-04|리제너론 파마슈티칼스 인코포레이티드|Readily isolated bispecific antibodies with native immunoglobulin format|

---

ES2777901T3|2009-12-25|2020-08-06|Chugai Pharmaceutical Co Ltd|Polypeptide Modification Method to Purify Polypeptide Multimers|

---

TWI609698B|2010-01-20|2018-01-01|Chugai Pharmaceutical Co Ltd|Stabilized antibody-containing solution preparation|

---

JP5820800B2|2010-03-02|2015-11-24|協和発酵キリン株式会社|Modified antibody composition|

---

EP2545079A2|2010-03-11|2013-01-16|Rinat Neuroscience Corporation|ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING|

---

JP5998050B2|2010-03-31|2016-09-28|Jsr株式会社|Affinity chromatography packing|

---

US9150663B2|2010-04-20|2015-10-06|Genmab A/S|Heterodimeric antibody Fc-containing proteins and methods for production thereof|

---

CA2796633C|2010-04-23|2020-10-27|Genentech, Inc.|Production of heteromultimeric proteins|

---

CA2797981C|2010-05-14|2019-04-23|Rinat Neuroscience Corporation|Heterodimeric proteins and methods for producing and purifying them|

---

EP2603526A1|2010-08-13|2013-06-19|Medimmune Limited|Monomeric polypeptides comprising variant fc regions and methods of use|

---

EP2635607B1|2010-11-05|2019-09-04|Zymeworks Inc.|Stable heterodimeric antibody design with mutations in the fc domain|

---

US9334331B2|2010-11-17|2016-05-10|Chugai Seiyaku Kabushiki Kaisha|Bispecific antibodies|

---

AU2012235758B2|2011-03-25|2015-05-07|Ichnos Sciences SA|Hetero-dimeric immunoglobulins|

---

US10344050B2|2011-10-27|2019-07-09|Genmab A/S|Production of heterodimeric proteins|

---

EP2787078B1|2011-10-31|2019-05-22|Chugai Seiyaku Kabushiki Kaisha|Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain|

---

DK2773671T3|2011-11-04|2021-11-15|Zymeworks Inc|DESIGN OF STABLE HETERODIMED ANTIBODY WITH MUTATIONS IN THE FC DOMAIN|

---

CA2889951A1|2012-11-02|2014-05-08|Zymeworks Inc.|Crystal structures of heterodimeric fc domains|

---

PT2794905T|2011-12-20|2020-06-30|Medimmune Llc|Modified polypeptides for bispecific antibody scaffolds|

---

GB201203071D0|2012-02-22|2012-04-04|Ucb Pharma Sa|Biological products|

---

GB201203051D0|2012-02-22|2012-04-04|Ucb Pharma Sa|Biological products|

---

MY166045A|2012-03-08|2018-05-22|Hoffmann La Roche|Abeta antibody formulation|

---

US9815909B2|2012-03-13|2017-11-14|Novimmune S.A.|Readily isolated bispecific antibodies with native immunoglobulin format|

---

US20150196637A1|2012-04-20|2015-07-16|Merus B.V.|Methods and means for the production of ig-like molecules|

---

JP6309521B2|2012-08-13|2018-04-11|リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ．|Anti-PCSK9 antibody with pH-dependent binding properties|

---

KR102134305B1|2012-09-28|2020-07-15|추가이 세이야쿠 가부시키가이샤|Method for evaluating blood coagulation reaction|

---

US9714291B2|2012-10-05|2017-07-25|Kyowa Hakko Kirin Co., Ltd|Heterodimer protein composition|

---

UY35148A|2012-11-21|2014-05-30|Amgen Inc|HETERODIMERIC IMMUNOGLOBULINS|

---

KR20210070401A|2012-11-28|2021-06-14|자임워크스 인코포레이티드|Engineered immunoglobulin heavy chain-light chain pairs and uses thereof|

---

ES2699599T3|2013-03-15|2019-02-11|Abbvie Biotherapeutics Inc|Fc variants|

---

ES2881306T3|2013-09-27|2021-11-29|Chugai Pharmaceutical Co Ltd|Method for the production of heteromultimers of polypeptides|

---

WO2015063339A1|2013-11-04|2015-05-07|Glenmark Pharmaceuticals S.A.|Production of t cell retargeting hetero-dimeric immunoglobulins|

---

ES2747749T3|2014-04-02|2020-03-11|Hoffmann La Roche|Multispecific antibodies|

---

EP3107938A4|2014-05-28|2018-02-28|Zymeworks, Inc.|Modified antigen binding polypeptide constructs and uses thereof|

---

TW201625299A|2014-06-20|2016-07-16|Chugai Pharmaceutical Co Ltd|Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii|

---

TWI701435B|2014-09-26|2020-08-11|日商中外製藥股份有限公司|Method to determine the reactivity of FVIII|

---

TWI700300B|2014-09-26|2020-08-01|日商中外製藥股份有限公司|Antibodies that neutralize substances with the function of FVIII coagulation factor |

---

JP6630036B2|2014-09-30|2020-01-15|Jsr株式会社|Method for purifying target substance and carrier for mixed mode|

---

EP3279216A4|2015-04-01|2019-06-19|Chugai Seiyaku Kabushiki Kaisha|Method for producing polypeptide hetero-oligomer|

---

JP2018123055A|2015-04-24|2018-08-09|公立大学法人奈良県立医科大学|Pharmaceutical composition for use in prevention and/or treatment of blood coagulation factor xi abnormalities comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |

---

US20200270363A1|2015-12-25|2020-08-27|Chugai Seiyaku Kabushiki Kaisha|Antibody having enhanced activity, and method for modifying same|

---

MX2018007781A|2015-12-28|2018-09-05|Chugai Pharmaceutical Co Ltd|Method for promoting efficiency of purification of fc region-containing polypeptide.|

---

WO2017188356A1|2016-04-28|2017-11-02|中外製薬株式会社|Antibody-containing preparation|

---

CA3025162A1|2016-05-26|2017-11-30|Qilu Puget Sound Biotherapeutics Corporation|Mixtures of antibodies|

---

RU2745648C2|2016-07-19|2021-03-30|Ибентрус, Инк.|Bispecific proteins and methods of their production|

---

JPWO2018021450A1|2016-07-29|2019-05-23|中外製薬株式会社|Bispecific antibodies having enhanced FVIII cofactor alternative activity|

---

WO2018047813A1|2016-09-06|2018-03-15|Chugai Seiyaku Kabushiki Kaisha|Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x|

---

KR102078957B1|2017-09-29|2020-02-20|추가이 세이야쿠 가부시키가이샤|Multispecific antigen binding molecules having blood coagulation factor VIII carrier replacement activity and pharmaceutical preparations containing the molecules as active ingredients|WO2006106905A1|2005-03-31|2006-10-12|Chugai Seiyaku Kabushiki Kaisha|Process for production of polypeptide by regulation of assembly|

---

US11046784B2|2006-03-31|2021-06-29|Chugai Seiyaku Kabushiki Kaisha|Methods for controlling blood pharmacokinetics of antibodies|

---

ES2654040T3|2006-03-31|2018-02-12|Chugai Seiyaku Kabushiki Kaisha|Antibody modification method for the purification of bispecific antibodies|

---

PL2202245T3|2007-09-26|2017-02-28|Chugai Seiyaku Kabushiki Kaisha|Method of modifying isoelectric point of antibody via amino acid substitution in cdr|

---

US20120071634A1|2009-03-19|2012-03-22|Chugai Seiyaku Kabushiki Kaisha|Antibody Constant Region Variant|

---

WO2010107110A1|2009-03-19|2010-09-23|中外製薬株式会社|Antibody constant region variant|

---

ES2777901T3|2009-12-25|2020-08-06|Chugai Pharmaceutical Co Ltd|Polypeptide Modification Method to Purify Polypeptide Multimers|

---

JP5889181B2|2010-03-04|2016-03-22|中外製薬株式会社|Antibody constant region variants|

---

US9334331B2|2010-11-17|2016-05-10|Chugai Seiyaku Kabushiki Kaisha|Bispecific antibodies|

---

TWI685503B|2010-11-30|2020-02-21|中外製藥股份有限公司|Cell injury-inducing therapeutic agent|

---

US8790651B2|2011-07-21|2014-07-29|Zoetis Llc|Interleukin-31 monoclonal antibody|

---

AU2013259276B2|2012-05-10|2018-03-22|Bioatla Llc|Multi-specific monoclonal antibodies|

---

KR102134305B1|2012-09-28|2020-07-15|추가이 세이야쿠 가부시키가이샤|Method for evaluating blood coagulation reaction|

---

ES2881306T3|2013-09-27|2021-11-29|Chugai Pharmaceutical Co Ltd|Method for the production of heteromultimers of polypeptides|

---

CN105294857B|2014-06-18|2019-02-19|上海交通大学|Epitope and its application based on FIX|

---

TW201625299A|2014-06-20|2016-07-16|Chugai Pharmaceutical Co Ltd|Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii|

---

TWI700300B|2014-09-26|2020-08-01|日商中外製藥股份有限公司|Antibodies that neutralize substances with the function of FVIII coagulation factor |

---

TWI701435B|2014-09-26|2020-08-11|日商中外製藥股份有限公司|Method to determine the reactivity of FVIII|

---

SG11201706014PA|2015-02-05|2017-08-30|Chugai Pharmaceutical Co Ltd|Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof|

---

EP3279216A4|2015-04-01|2019-06-19|Chugai Seiyaku Kabushiki Kaisha|Method for producing polypeptide hetero-oligomer|

---

JP6698102B2|2015-04-17|2020-05-27|エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ|Combination therapy with coagulation factors and multispecific antibodies|

---

JP2018123055A|2015-04-24|2018-08-09|公立大学法人奈良県立医科大学|Pharmaceutical composition for use in prevention and/or treatment of blood coagulation factor xiabnormalities comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |

---

CN107533071A|2015-04-24|2018-01-02|公立大学法人奈良县立医科大学|The evaluation method of the coagulation ability of blood subject and reagent, kit and device for using in the method|

---

EP3330279A4|2015-07-31|2019-01-02|Chugai Seiyaku Kabushiki Kaisha|Method for purifying composition comprising antibodies with anionic polymer|

---

MA42808A|2015-09-18|2018-07-25|Chugai Pharmaceutical Co Ltd|IL-8 BINDING ANTIBODIES AND THEIR USES|

---

US20200270363A1|2015-12-25|2020-08-27|Chugai Seiyaku Kabushiki Kaisha|Antibody having enhanced activity, and method for modifying same|

---

WO2017188356A1|2016-04-28|2017-11-02|中外製薬株式会社|Antibody-containing preparation|

---

JPWO2018021450A1|2016-07-29|2019-05-23|中外製薬株式会社|Bispecific antibodies having enhanced FVIII cofactor alternative activity|

---

WO2018047813A1|2016-09-06|2018-03-15|Chugai Seiyaku Kabushiki Kaisha|Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x|

---

EP3515948A4|2016-09-23|2020-04-08|CSL Limited|Coagulation factor binding proteins and uses thereof|

---

JP2019535325A|2016-11-23|2019-12-12|バイオベラティブ セラピューティクス インコーポレイテッド|Bispecific antibody binding to coagulation factor IX and coagulation factor X|

---

BR112019015611A2|2017-02-01|2020-03-17|Novo Nordisk A/S|PRO-COAGULANT ANTIBODIES|

---

US20210107994A1|2017-03-31|2021-04-15|Public University Corporation Nara Medical University|Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii|

---

GB201709970D0|2017-06-22|2017-08-09|Kymab Ltd|Bispecific antigen-binding molecules|

---

CA3073537A1|2017-08-22|2019-02-28|Sanabio, Llc|Soluble interferon receptors and uses thereof|

---

KR102078957B1|2017-09-29|2020-02-20|추가이 세이야쿠 가부시키가이샤|Multispecific antigen binding molecules having blood coagulation factor VIIIcarrier replacement activity and pharmaceutical preparations containing the molecules as active ingredients|

---

TW201930352A|2017-11-01|2019-08-01|日商中外製藥股份有限公司|Antibody variants and isoforms with reduced biological activity|

---

MA50893A|2017-11-15|2020-09-23|Novo Nordisk As|X-FACTOR BINDERS REINFORCING FX ACTIVATION|

---

EP3797752A4|2018-05-21|2022-03-02|Chugai Pharmaceutical Co Ltd|Lyophilized formulation sealed in glass vial|

---

US20210229848A1|2018-05-28|2021-07-29|Chugai Seiyaku Kabushiki Kaisha|Filling nozzle|

---

WO2019235420A1|2018-06-04|2019-12-12|中外製薬株式会社|Method for detecting complex|

---

FR3082427B1|2018-06-14|2020-09-25|Lab Francais Du Fractionnement|COMBINATION OF FACTOR VII AND A BISPECIFIC ANTIBODY ANTI-FACTORS IX AND X|

---

US11220554B2|2018-09-07|2022-01-11|Novo Nordisk A/S|Procoagulant antibodies|

---

BR112021000823A2|2018-08-01|2021-04-13|Novo Nordisk A/S|MULTI-SPECIFIC ANTIBODY OR ITS ANTIGEN BINDING FRAGMENT.|

---

EP3723858B1|2018-12-21|2021-10-27|Kymab Limited|Fixaxfx bispecific antibody with common light chain|

---

WO2021069504A1|2019-10-11|2021-04-15|F. Hoffmann-La Roche Ag|Drug dosage determination devices and methods|

---

WO2021152066A1|2020-01-30|2021-08-05|Novo Nordisk A/S|Bispecific factor viii mimetic antibodies|

---

WO2021210667A1|2020-04-17|2021-10-21|中外製薬株式会社|Bispecific antigen-binding molecule, composition associated therewith, and use, kit, and method for producing composition|

法律状态:
2020-09-15| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-10-27| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2021-07-20| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2021-08-17| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-11-23| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

JP2010-257022|2010-11-17|

---

JP2010257022|2010-11-17|

---

PCT/JP2011/076486|WO2012067176A1|2010-11-17|2011-11-17|Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii|

---